Cytarabine
Information
- Drug Name
- Cytarabine
- Description
- Entry(CIViC)
- 15
CIViC
Annotation
| Description | Associated Genes | Associated Variants | Sensitivity | Supported | Source | Links |
|---|---|---|---|---|---|---|
| WT1 mutations were associated with an inferior res... | WT1 | WT1 EXON 7 MUTATION WT1 EXON 7 MUTATION | Resitance or Non-Reponse | true | CIViC Evidence | detail |
| SU11248 + Cytarabin has a synergic effect on Murin... | FLT3 |
FLT3 p.Asp835Val (p.D835V) ( ENST00000241453.12 ) FLT3 p.Asp835Val (p.D835V) ( ENST00000241453.12 ) |
Sensitivity | true | CIViC Evidence | detail |
| In non-APL patients with AML (age 18-60), those wh... | RUNX1 | RUNX1 MUTATION RUNX1 MUTATION | Resitance or Non-Reponse | true | CIViC Evidence | detail |
| Lentiviral mediated overexpression of NT5C2 R367Q ... | NT5C2 |
NT5C2 p.Arg375Gln (p.R375Q) ( ENST00000675985.1, ENST00000675326.1, ENST00000674860.1, ENST00000674696.1, ENST00000676449.1, ENST00000404739.8, ENST00000675645.1, ENST00000676428.1, ENST00000343289.9 ) NT5C2 p.Arg375Gln (p.R375Q) ( ENST00000343289.9, ENST00000404739.8, ENST00000674696.1, ENST00000674860.1, ENST00000675326.1, ENST00000675645.1, ENST00000675985.1, ENST00000676428.1, ENST00000676449.1 ) |
Resitance or Non-Reponse | false | CIViC Evidence | detail |
| Overexpression of NT5C2 R238W in Reh cells resulte... | NT5C2 |
NT5C2 p.Arg246Trp (p.R246W) ( ENST00000676428.1, ENST00000343289.9, ENST00000675985.1, ENST00000674696.1, ENST00000674860.1, ENST00000675326.1, ENST00000675645.1, ENST00000404739.8, ENST00000676449.1 ) NT5C2 p.Arg246Trp (p.R246W) ( ENST00000675985.1, ENST00000343289.9, ENST00000404739.8, ENST00000674696.1, ENST00000674860.1, ENST00000675326.1, ENST00000675645.1, ENST00000676428.1, ENST00000676449.1 ) |
Resitance or Non-Reponse | false | CIViC Evidence | detail |
| Overexpression of NT5C2 S445F in Reh cells resulte... | NT5C2 |
NT5C2 p.Ser453Phe (p.S453F) ( ENST00000676449.1, ENST00000675985.1, ENST00000404739.8, ENST00000675645.1, ENST00000674860.1, ENST00000675326.1, ENST00000674696.1, ENST00000343289.9, ENST00000676428.1 ) NT5C2 p.Ser453Phe (p.S453F) ( ENST00000674860.1, ENST00000675326.1, ENST00000343289.9, ENST00000404739.8, ENST00000674696.1, ENST00000675645.1, ENST00000675985.1, ENST00000676428.1, ENST00000676449.1 ) |
Resitance or Non-Reponse | false | CIViC Evidence | detail |
| Lentiviral-mediated overexpression of PRPS1 N144S ... | PRPS1 | PRPS1 N144S PRPS1 N144S | Sensitivity | true | CIViC Evidence | detail |
| Lentiviral-mediated overexpression of PRPS1 L191F ... | PRPS1 | PRPS1 L191F PRPS1 L191F | Sensitivity | true | CIViC Evidence | detail |
| Lentiviral-mediated overexpression of PRPS1 S103T ... | PRPS1 | PRPS1 S103I PRPS1 S103I | Resitance or Non-Reponse | false | CIViC Evidence | detail |
| Lentiviral-mediated overexpression of PRPS1 S103N ... | PRPS1 | PRPS1 S103I PRPS1 S103I | Resitance or Non-Reponse | false | CIViC Evidence | detail |
| Lentiviral-mediated overexpression of PRPS1 K176N ... | PRPS1 | PRPS1 K176N PRPS1 K176N | Resitance or Non-Reponse | false | CIViC Evidence | detail |
| Lentiviral-mediated overexpression of PRPS1 D183E ... | PRPS1 | PRPS1 D183E PRPS1 D183E | Resitance or Non-Reponse | false | CIViC Evidence | detail |
| Lentiviral-mediated overexpression of PRPS1 A190T ... | PRPS1 | PRPS1 A190V PRPS1 A190V | Resitance or Non-Reponse | false | CIViC Evidence | detail |
| Lentiviral-mediated overexpression of PRPS1 T303S ... | PRPS1 | PRPS1 T303S PRPS1 T303S | Resitance or Non-Reponse | false | CIViC Evidence | detail |
| Downregulation of ZEB1 expression in mantle cell l... | ZEB1 | ZEB1 EXPRESSION ZEB1 EXPRESSION | Resitance or Non-Reponse | true | CIViC Evidence | detail |
| The marked synergy noted with pyrimidine-based ant... | ROS1 | ROS1 OVEREXPRESSION | Sensitivity | true | MMMP | detail |
| Cells were transfected with ATF2 cDNA lacking the ... | ATF2 | ATF2 UNDEREXPRESSION | Sensitivity | true | MMMP | detail |
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT03589326 | Active, not recruiting | Phase 3 | A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia | October 4, 2018 | July 31, 2027 |
| NCT02797470 | Active, not recruiting | Phase 1/Phase 2 | Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant | June 23, 2016 | June 30, 2025 |
| NCT04914676 | Active, not recruiting | Phase 2 | Accelerated Dose Schedule of Cytarabine Consolidation Therapy for Older Patients With Acute Myeloid Leukemia (AML) in Complete Remission | March 8, 2022 | December 2024 |
| NCT04115631 | Active, not recruiting | Phase 2 | A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma | December 13, 2019 | March 31, 2025 |
| NCT04107727 | Active, not recruiting | Phase 2 | Trial to Compare Efficacy and Safety of Chemotherapy/Quizartinib vs Chemotherapy/Placebo in Adults FMS-like Tyrosine Kinase 3 (FLT3) Wild-type Acute Myeloid Leukemia (AML) | September 5, 2019 | September 2024 |
| NCT03147612 | Active, not recruiting | Phase 2 | Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia | February 8, 2018 | February 28, 2025 |
| NCT02310321 | Active, not recruiting | Phase 1/Phase 2 | A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia. | February 26, 2015 | July 31, 2024 |
| NCT03117751 | Active, not recruiting | Phase 2/Phase 3 | Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma | March 29, 2017 | March 31, 2028 |
| NCT03568994 | Active, not recruiting | Early Phase 1 | Atovaquone (Mepron®) Combined With Conventional Chemotherapy for de Novo Acute Myeloid Leukemia (AML) | July 10, 2018 | October 31, 2025 |
| NCT02303821 | Active, not recruiting | Phase 1 | Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia | February 16, 2015 | July 14, 2024 |
| NCT02553460 | Active, not recruiting | Phase 1/Phase 2 | Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I | January 29, 2016 | October 2031 |
| NCT03467256 | Active, not recruiting | Phase 1/Phase 2 | CD19 T-CAR for Treatment of Children and Young Adults With r/r B-ALL | May 14, 2018 | October 15, 2025 |
| NCT03330821 | Active, not recruiting | Phase 1/Phase 2 | Pevonedistat, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia | April 18, 2018 | October 13, 2025 |
| NCT04029688 | Active, not recruiting | Phase 1/Phase 2 | A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid Tumors | January 27, 2020 | December 30, 2025 |
| NCT02112916 | Active, not recruiting | Phase 3 | Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma | October 4, 2014 | September 22, 2024 |
| NCT02101853 | Active, not recruiting | Phase 3 | Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia | December 17, 2014 | September 22, 2024 |
| NCT02756962 | Active, not recruiting | Phase 2 | Improving Risk Assessment of AML With a Precision Genomic Strategy to Assess Mutation Clearance | July 6, 2016 | July 31, 2033 |
| NCT02085408 | Active, not recruiting | Phase 3 | Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia | February 4, 2011 | October 2024 |
| NCT04848974 | Active, not recruiting | Phase 1/Phase 2 | Uproleselan, Cladribine, and Low Dose Cytarabine for the Treatment of Patients With Treated Secondary Acute Myeloid Leukemia | June 11, 2021 | December 31, 2026 |
| NCT02003222 | Active, not recruiting | Phase 3 | Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia | May 19, 2014 | December 4, 2024 |
| NCT03964090 | Active, not recruiting | Phase 2 | Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas With Secondary Involvement of the Central Nervous System (CNS) | June 27, 2019 | July 1, 2026 |
| NCT01920737 | Active, not recruiting | Phase 2 | A Novel "Pediatric-Inspired" Regimen With Reduced Myelosuppressive Drugs for Adults (Aged 18-60) With Newly Diagnosed Ph Negative Acute Lymphoblastic Leukemia | August 2013 | August 2024 |
| NCT01840566 | Active, not recruiting | Phase 1 | High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma | April 2013 | April 2025 |
| NCT03962465 | Active, not recruiting | Phase 1 | Phase I Study of Inotuzumab With Augmented BFM Re-Induction for Patients With Relapsed/Refractory B-cell ALL | July 22, 2022 | July 2026 |
| NCT01661881 | Active, not recruiting | Phase 2 | Rituximab/Bendamustine + Rituximab/Cytarabine for Mantle Cell Lymphoma | August 16, 2012 | March 2025 |
| NCT05192889 | Active, not recruiting | Phase 1/Phase 2 | Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navitoclax | August 25, 2022 | July 2029 |
| NCT02723994 | Active, not recruiting | Phase 2 | A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia | September 30, 2016 | February 1, 2026 |
| NCT03836209 | Active, not recruiting | Phase 2 | Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia | December 6, 2019 | December 2024 |
| NCT02521493 | Active, not recruiting | Phase 3 | Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome | December 23, 2015 | June 30, 2024 |
| NCT02481310 | Active, not recruiting | Phase 1/Phase 2 | Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin Lymphoma | October 28, 2015 | July 2024 |
| NCT05177731 | Active, not recruiting | Phase 3 | Venetoclax + Decitabine vs. "7+3" Induction Chemotherapy in Young AML | March 1, 2022 | December 31, 2024 |
| NCT03226418 | Active, not recruiting | Phase 2 | Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid Leukemia | July 7, 2017 | October 7, 2024 |
| NCT02443077 | Active, not recruiting | Phase 3 | Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma | October 12, 2016 | May 10, 2025 |
| NCT00408005 | Active, not recruiting | Phase 3 | Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma | January 22, 2007 | March 7, 2025 |
| NCT01511562 | Active, not recruiting | Phase 2 | Combination Chemotherapy With or Without Autologous Stem Cell Transplant in Treating Patients With Central Nervous System B-Cell Lymphoma | September 2012 | |
| NCT02427620 | Active, not recruiting | Phase 2 | Ibrutinib, Rituximab, and Consolidation Chemotherapy in Treating Young Patients With Newly Diagnosed Mantle Cell Lymphoma | June 3, 2015 | June 30, 2025 |
| NCT03164057 | Active, not recruiting | Phase 2 | A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia | June 15, 2017 | June 2027 |
| NCT00136435 | Active, not recruiting | Phase 2 | A Study in Adults With Untreated Acute Lymphoblastic Leukemia | June 2002 | July 2024 |
| NCT01476839 | Active, not recruiting | Phase 1 | Radiolabeled Monoclonal Antibody Therapy and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Primary Refractory or Relapsed Hodgkin Lymphoma | November 9, 2012 | December 31, 2024 |
| NCT04229979 | Active, not recruiting | Phase 3 | Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2 | February 8, 2021 | March 2025 |
| NCT04817241 | Active, not recruiting | Phase 1/Phase 2 | Testing Oral Decitabine and Cedazuridine (ASTX727) in Combination With Venetoclax for Higher-Risk Acute Myeloid Leukemia Patients | February 10, 2022 | August 1, 2024 |
| NCT01424982 | Active, not recruiting | Phase 2 | Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia | October 5, 2011 | October 31, 2025 |
| NCT02688140 | Active, not recruiting | Phase 3 | Study for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia | June 2016 | January 2025 |
| NCT04293562 | Active, not recruiting | Phase 3 | A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations | July 21, 2020 | September 30, 2027 |
| NCT03092674 | Active, not recruiting | Phase 2/Phase 3 | Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | February 2, 2018 | October 29, 2024 |
| NCT04217278 | Active, not recruiting | Phase 2/Phase 3 | A Trial of Treatments to Assess the Effects on Outcome of Adults With AML and MDS Undergoing Allogeneic SCT | January 27, 2020 | March 2025 |
| NCT02392429 | Active, not recruiting | Phase 2 | FLT PET/CT in Measuring Response in Patients With Previously Untreated Acute Myeloid Leukemia | April 20, 2016 | February 13, 2025 |
| NCT02658487 | Active, not recruiting | Phase 2 | Vosaroxin and Infusional Cytarabine in Treating Patients With Untreated Acute Myeloid Leukemia | March 2016 | September 2024 |
| NCT04190550 | Active, not recruiting | Phase 1 | Testing the Addition of an Anti-cancer Drug, Navtemadlin, to the Usual Treatments (Cytarabine and Idarubicin) in Patients With Acute Myeloid Leukemia | February 4, 2021 | June 30, 2025 |
| NCT03069352 | Active, not recruiting | Phase 3 | A Study of Venetoclax in Combination With Low Dose Cytarabine Versus Low Dose Cytarabine Alone in Treatment Naive Patients With Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy | May 23, 2017 | July 18, 2024 |
| NCT04158739 | Active, not recruiting | Phase 1 | Flotetuzumab for the Treatment of Pediatric Recurrent or Refractory Acute Myeloid Leukemia | January 22, 2020 | September 22, 2024 |
| NCT03808610 | Active, not recruiting | Phase 1/Phase 2 | Low-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or Refractory B- or T-Cell Acute Lymphoblastic Leukemia | April 3, 2019 | December 31, 2026 |
| NCT00476190 | Active, not recruiting | Phase 2 | ALL Adult Consortium Trial: Adult ALL Trial | April 2007 | December 2024 |
| NCT03020030 | Active, not recruiting | Phase 3 | Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents | March 3, 2017 | November 2034 |
| NCT02632708 | Active, not recruiting | Phase 1 | Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation | December 31, 2015 | July 2024 |
| NCT01371981 | Active, not recruiting | Phase 3 | Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | June 20, 2011 | September 30, 2027 |
| NCT03792256 | Active, not recruiting | Phase 1 | Palbociclib in Combination With Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL) | April 11, 2019 | June 30, 2025 |
| NCT03710772 | Active, not recruiting | Phase 2 | Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma | May 1, 2019 | May 22, 2025 |
| NCT02883049 | Active, not recruiting | Phase 3 | Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations | February 29, 2012 | September 22, 2024 |
| NCT01228331 | Active, not recruiting | Phase 2/Phase 3 | Clofarabine or High-Dose Cytarabine and Pegaspargase in Children With ALL | October 2010 | December 2024 |
| NCT01190930 | Active, not recruiting | Phase 3 | Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma | August 9, 2010 | March 31, 2028 |
| NCT04526795 | Active, not recruiting | Phase 1 | Fludarabine, Cytarabine, and Pegcrisantaspase for the Treament of Relapsed or Refractory Leukemia | April 9, 2021 | December 31, 2024 |
| NCT01085617 | Active, not recruiting | Phase 3 | Standard Chemotherapy With or Without Nelarabine or Rituximab in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia | December 2010 | December 2025 |
| NCT02342782 | Active, not recruiting | Phase 1 | Yttrium Y 90 Basiliximab and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Mature T-cell Non-Hodgkin Lymphoma | June 8, 2020 | December 31, 2024 |
| NCT00878254 | Active, not recruiting | Phase 2 | Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated Mantle Cell Lymphoma | March 25, 2009 | September 2027 |
| NCT02339740 | Active, not recruiting | Phase 3 | Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia | July 21, 2015 | September 22, 2024 |
| NCT00792948 | Active, not recruiting | Phase 2 | Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia | September 1, 2009 | January 6, 2025 |
| NCT02329080 | Active, not recruiting | Phase 2 | New Combination of Chemoimmunotherapy for Systemic B-cell Lymphoma With Central Nervous System Involvement | December 2014 | December 2023 |
| NCT03623373 | Active, not recruiting | Phase 2 | Acalabrutinib With Bendamustine / Rituximab Followed by Cytarabine / Rituximab for Untreated Mantle Cell Lymphoma | November 29, 2018 | February 5, 2025 |
| NCT00534469 | Active, not recruiting | Phase 2 | Auto BMT for Non-M3 AML in 1st Remission in Pts </=60y of Age Using Busulfan/FTBI & VP16 as a Prep R | February 8, 2000 | December 30, 2024 |
| NCT02881086 | Active, not recruiting | Phase 3 | Optimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment | August 2016 | July 2025 |
| NCT00716066 | Active, not recruiting | Phase 2 | Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases | June 2008 | January 31, 2030 |
| NCT00557193 | Active, not recruiting | Phase 3 | Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia | January 15, 2008 | June 28, 2024 |
| NCT02828358 | Active, not recruiting | Phase 2 | Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement | April 1, 2017 | September 22, 2024 |
| NCT00004231 | Completed | Phase 2 | Combination Chemotherapy, Bone Marrow or Peripheral Stem Cell Transplantation, and/or Biological Therapy in Treating Patients With Stage III or Stage IV Mantle Cell Lymphoma | October 1999 | August 2006 |
| NCT00004643 | Completed | Phase 2 | Phase II Pilot Study of Cytarabine for Refractory Systemic Lupus Erythematosus | February 1995 | |
| NCT00004862 | Completed | Phase 1 | Augmerosen Plus Fludarabine and Cytarabine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia | October 1999 | |
| NCT00004905 | Completed | Phase 2 | Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous Leukemia or Acute Leukemia | October 1999 | September 2004 |
| NCT00005585 | Completed | Phase 3 | Combination Chemotherapy in Treating Children With Acute Lymphoblastic Leukemia | April 2000 | |
| NCT00005589 | Completed | Phase 3 | Combination Chemotherapy Plus Peripheral Stem Cell Transplantation With or Without Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma | October 1999 | April 2013 |
| NCT00005596 | Completed | Phase 3 | Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Lymphoblastic Leukemia | April 2000 | July 2007 |
| NCT00005601 | Completed | Phase 2 | Combination Chemotherapy Plus Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma | October 2000 | February 2008 |
| NCT00005603 | Completed | Phase 3 | Combination Chemotherapy in Treating Children With Acute Lymphoblastic Leukemia | March 2000 | |
| NCT00005793 | Completed | Phase 1/Phase 2 | A Phase I/II Study of Induction Chemotherapy With Daunorubicin, Cytarabine, Topotecan and Etoposide | July 1999 | November 2006 |
| NCT00005802 | Completed | Phase 1/Phase 2 | Chemotherapy Followed by Donor White Blood Cells Plus Interleukin-2 in Treating Patients With Acute Myeloid or Lymphocytic Leukemia | June 1999 | March 2005 |
| NCT00005803 | Completed | Phase 1/Phase 2 | Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoma | September 1999 | October 2018 |
| NCT00005823 | Completed | Phase 3 | Intensive Compared With Nonintensive Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome | December 1998 | December 2007 |
| NCT00005863 | Completed | Phase 3 | Combination Chemotherapy With or Without Filgrastim and/or Tretinoin in Treating Patients With Acute Myeloid Leukemia | August 1998 | December 2004 |
| NCT00005945 | Completed | Phase 3 | Comparison of Different Combination Chemotherapy Regimens in Treating Children With Acute Lymphoblastic Leukemia | June 2000 | June 2008 |
| NCT00005962 | Completed | Phase 2 | Comparison of Three Treatment Regimens in Treating Patients With Relapsed or Refractory Acute Myelogenous Leukemia | October 4, 2000 | June 2007 |
| NCT00005977 | Completed | Phase 3 | Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma or Acute Lymphocytic Leukemia | September 2000 | September 2006 |
| NCT00005985 | Completed | Phase 2 | Filgrastim and Chemotherapy Followed by Peripheral Stem Cell Transplant in Treating Patients With Hodgkin's Lymphoma or Non-Hodgkin's Lymphoma | August 2000 | February 2007 |
| NCT00006122 | Completed | Phase 2 | Gemtuzumab Ozogamicin With or Without Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia | June 2000 | |
| NCT00006343 | Completed | Phase 3 | STI571 Compared With Interferon Alfa Plus Cytarabine in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia | June 2000 | March 2007 |
| NCT00006363 | Completed | Phase 3 | Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid Leukemia | November 2000 | |
| NCT00006367 | Completed | Phase 2 | Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Myelofibrosis | May 2000 | January 2004 |
| NCT00006455 | Completed | Phase 3 | Combination Chemotherapy in Treating Children With Anaplastic Large Cell Lymphoma (ALCL 99) | November 26, 1999 | September 3, 2020 |
| NCT00006695 | Completed | Phase 2 | Monoclonal Antibody Therapy, Combination Chemotherapy, and Peripheral Stem Cell Transplant in Non-Hodgkin's Lymphoma | April 1, 2000 | December 16, 2014 |
| NCT00006747 | Completed | Phase 2 | Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Mantle Cell Lymphoma | November 2000 | February 2003 |
| NCT00007852 | Completed | Phase 2 | Rituximab & Combination Chemotherapy Followed by Transplantation in Relapsed or Refractory Non-Hodgkin's Lymphoma | September 1, 2000 | January 1, 2011 |
| NCT00012051 | Completed | Phase 3 | Chemotherapy and Peripheral Stem Cell Transplant With or Without Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma | September 2000 | October 2007 |
| NCT00014495 | Completed | Phase 1/Phase 2 | Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Advanced Myeloid Cancer | November 2000 | December 2009 |
| NCT00015834 | Completed | Phase 1/Phase 2 | STI571 Plus Cytarabine in Treating Patients With Chronic Myelogenous Leukemia | May 2001 | |
| NCT00015873 | Completed | Phase 3 | Comparison of Different Combination Chemotherapy Regimens in Treating Infants With Acute Lymphoblastic Leukemia | May 1999 | December 2009 |
| NCT00015951 | Completed | Phase 2 | Bevacizumab, Cytarabine, and Mitoxantrone on Treating Patients With Hematologic Cancers | April 2001 | March 2004 |
| NCT00016016 | Completed | Phase 1/Phase 2 | Flavopiridol, Cytarabine, and Mitoxantrone in Treating Patients With Acute Leukemia | February 2001 | |
| NCT00016302 | Completed | N/A | Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia | April 2001 | |
| NCT00017342 | Completed | Phase 2 | Bryostatin 1 and Cytarabine in Treating Patients With Relapsed Acute Myelogenous Leukemia | July 2001 | June 2005 |
| NCT00018954 | Completed | Phase 2 | Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia and Diffuse Non-Hodgkin's Lymphoma | October 1992 | October 2002 |
| NCT00020943 | Completed | Phase 2 | Chemotherapy and Rituximab With Peripheral Stem Cell Transplantation in Treating Patients With Mantle Cell Lymphoma | June 2001 | September 2009 |
| NCT00022126 | Completed | Phase 2 | Combination Chemotherapy With or Without Donor Bone Marrow Transplantation in Treating Infants With Previously Untreated Acute Lymphoblastic Leukemia | November 2002 | April 2006 |
| NCT00022737 | Completed | Phase 3 | Combination Chemotherapy With or Without Peripheral Stem Cell Transplant in Treating Children With Acute Lymphoblastic Leukemia | October 2002 | |
| NCT00023777 | Completed | Phase 2 | S0112 Cytarabine and Daunorubicin in Treating Older Patients With Acute Myeloid Leukemia | August 2001 | April 2008 |
| NCT00025038 | Completed | Phase 2 | Combination Chemotherapy Followed By Donor Bone Marrow or Umbilical Cord Blood Transplant in Treating Children With Newly Diagnosed Juvenile Myelomonocytic Leukemia | June 2001 | |
| NCT00025259 | Completed | Phase 3 | Chemotherapy With or Without Additional Chemotherapy and/or Radiation Therapy in Treating Children With Newly Diagnosed Hodgkin's Disease | September 2002 | |
| NCT00027547 | Completed | Phase 1/Phase 2 | Combination Chemotherapy and Total-Body Irradiation Followed by Peripheral Stem Cell or Bone Marrow Transplantation in Treating Patients With Acute Lymphoblastic Leukemia | July 2001 | July 2004 |
| NCT00028899 | Completed | Phase 1 | Monoclonal Antibody Plus Chemotherapy in Treating Young Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes | July 2002 | March 2012 |
| NCT00038610 | Completed | Phase 2 | Study of Hyper-CVAD Plus Imatinib Mesylate for Philadelphia-Positive Acute Lymphocytic Leukemia | March 2001 | July 2014 |
| NCT00039117 | Completed | Phase 1 | Oblimersen, Cytarabine, and Daunorubicin in Treating Older Patients With Acute Myeloid Leukemia | April 2002 | |
| NCT00039130 | Completed | Phase 2 | Rituximab, Chemotherapy, and Filgrastim in Treating Patients With Burkitt's Lymphoma or Burkitt's Leukemia | May 2002 | October 2014 |
| NCT00039377 | Completed | Phase 2 | Chemotherapy, Imatinib Mesylate, and Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia | April 2002 | February 2014 |
| NCT00040690 | Completed | Phase 2 | Combination Chemotherapy in Treating Patients With Burkitt's Lymphoma or Burkitt's Leukemia | November 2008 | December 2008 |
| NCT00041132 | Completed | Phase 2 | S0213 Chemotherapy Plus Rituximab in Treating Patients With Mantle Cell Lymphoma | September 2002 | June 2011 |
| NCT00046930 | Completed | Phase 3 | Daunorubicin & Cytarabine +/- Zosuquidar inTreating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or Refractory Anemia | September 17, 2002 | |
| NCT00047021 | Completed | Phase 2 | Combination Chemotherapy in Treating Patients With Recurrent or Refractory Leukemia or Lymphoma | November 2001 | September 2005 |
| NCT00049179 | Completed | Phase 2 | S0117 Gemtuzumab Ozogamicin Plus Cytarabine in Treating Patients With Relapsed Acute Myeloid Leukemia | April 2003 | October 2010 |
| NCT00049517 | Completed | Phase 3 | Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With AML Leukemia | December 19, 2002 | December 2019 |
| NCT00049569 | Completed | N/A | Combination Chemotherapy and Imatinib Mesylate in Treating Children With Relapsed Acute Lymphoblastic Leukemia | January 2003 | |
| NCT00052299 | Completed | Phase 3 | Chemotherapy With or Without Gemtuzumab Ozogamicin in Treating Older Patients With Acute Myeloid Leukemia | September 2002 | February 2012 |
| NCT00053131 | Completed | Phase 2 | Combination Chemotherapy Followed By Filgrastim or Sargramostim in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia | January 1999 | February 2004 |
| NCT00053144 | Completed | Phase 1 | Irinotecan and Cytarabine in Treating Patients With Refractory or Recurrent Acute Myeloid Leukemia or Chronic Myelogenous Leukemia | November 1999 | March 2003 |
| NCT00054327 | Completed | Phase 2 | Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer | November 2000 | September 2011 |
| NCT00055874 | Completed | Phase 3 | Imatinib Mesylate With or Without Interferon Alfa or Cytarabine Compared With Interferon Alfa Followed by Donor Stem Cell Transplant in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia | June 2002 | March 31, 2017 |
| NCT00057811 | Completed | Phase 2 | Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma | June 2004 | July 2014 |
| NCT00058292 | Completed | Phase 1 | Radiolabeled Monoclonal Antibody Therapy and High-Dose Chemotherapy Followed By Autologous Peripheral Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma | April 2000 | March 2009 |
| NCT00061945 | Completed | Phase 1/Phase 2 | Alemtuzumab and Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia | June 2003 | October 2012 |
| NCT00064090 | Completed | Phase 1 | 3-AP and Cytarabine in Treating Patients With Hematologic Cancer | March 2003 | January 2008 |
| NCT00066794 | Completed | Phase 2 | S0301 Cyclosporine, Daunorubicin, and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia | July 2004 | January 2010 |
| NCT00070174 | Completed | Phase 2 | Gemtuzumab Ozogamicin in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia Undergoing Remission Induction and Intensification Therapy | December 2003 | December 2013 |
| NCT00070187 | Completed | Phase 2/Phase 3 | Immunotherapy Using Cyclosporine, Interferon Gamma, and Interleukin-2 After High-Dose Myeloablative Chemotherapy With Autologous Stem Cell Transplantation in Treating Patients With Refractory or Relapsed Hodgkin's Lymphoma | November 2003 | |
| NCT00070538 | Completed | Phase 1 | VNP40101M and Cytarabine in Treating Patients With Hematologic Malignancies | June 2003 | January 2008 |
| NCT00070551 | Completed | Phase 1 | GTI-2040 and High-Dose Cytarabine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia | September 2003 | |
| NCT00073957 | Completed | Phase 2 | Y 90 Ibritumomab Tiuxetan &Rituximab Relapsed or Refractory Diffuse Large B-Cell Non-Hodgkin's Lymphoma | December 2003 | January 1, 2012 |
| NCT00074178 | Completed | Phase 2 | Methotrexate, Cyclophosphamide, and Etoposide Phosphate Given With Osmotic Blood-Brain Barrier Disruption Plus Dexamethasone and Cytarabine in Treating Patients With Primary CNS Lymphoma | January 2000 | July 2006 |
| NCT00074191 | Completed | Phase 2 | Methotrexate, Procarbazine, Lomustine, Dexamethasone, and Cytarabine in Treating Patients With Primary CNS Lymphoma | January 2000 | October 2000 |
| NCT00074737 | Completed | Phase 2 | Dosing Study of Ara-C/EL625/Idarubicin in Refractory and Relapsed AML | April 2004 | May 2007 |
| NCT00075725 | Completed | Phase 3 | Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia | December 29, 2003 | March 31, 2021 |
| NCT00077116 | Completed | Phase 2 | Idarubicin, Cytarabine, and Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia Secondary to Myelodysplastic Syndrome | November 2003 | |
| NCT00077181 | Completed | Phase 1 | 3-AP and High-Dose Cytarabine in Treating Patients With Advanced Hematologic Malignancies | January 2004 | |
| NCT00078949 | Completed | Phase 3 | Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma | August 27, 2003 | December 2018 |
| NCT00080886 | Completed | Phase 2 | Rituximab, Carmustine; Cytarabine, Etoposide, & Melphalan; Stem Cell Transplantation for Non-Hodgkin's Lymphoma | May 8, 2002 | March 12, 2015 |
| NCT00080925 | Completed | Phase 1 | T-Cell-Depleted Allogeneic Stem Cell Transplantation After Immunoablative Induction Chemotherapy and Reduced-Intensity Transplantation Conditioning in Treating Patients With Hematologic Malignancies | February 2004 | December 2010 |
| NCT00084838 | Completed | Phase 2 | Chemotherapy Combined With Radiation Therapy for Newly Diagnosed CNS AT/RT | February 2003 | March 2013 |
| NCT00085124 | Completed | Phase 3 | Daunorubicin Hydrochloride, Cytarabine and Oblimersen Sodium in Treating Patients With Previously Untreated Acute Myeloid Leukemia | December 2003 | |
| NCT00093483 | Completed | Phase 1 | Arsenic Trioxide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia | April 2002 | December 2009 |
| NCT00093600 | Completed | Phase 1 | PKC412, Daunorubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | February 2004 | June 2011 |
| NCT00096122 | Completed | Phase 1/Phase 2 | Idarubicin, Cytarabine, and Tipifarnib in Treating Patients With Newly Diagnosed Myelodysplastic Syndromes or Acute Myeloid Leukemia | September 2004 | February 2010 |
| NCT00096135 | Completed | N/A | Combination Chemotherapy and Radiation Therapy in Treating Patients With Acute Lymphoblastic Leukemia That Has Relapsed in the CNS or Testes | November 2004 | |
| NCT00098423 | Completed | Phase 1 | Tanespimycin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Chronic Myelomonocytic Leukemia, or Myelodysplastic Syndromes | November 2004 | |
| NCT00098774 | Completed | Phase 2 | Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Primary CNS Lymphoma | October 2004 | September 2014 |
| NCT00098839 | Completed | Phase 1/Phase 2 | Chemoimmunotherapy With Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL) | February 2005 | April 2011 |
| NCT00101153 | Completed | Phase 1 | Tipifarnib, Cytarabine, and Daunorubicin in Treating Older Patients With Acute Myeloid Leukemia | April 2007 | |
| NCT00103285 | Completed | Phase 3 | Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia | April 11, 2005 | March 31, 2021 |
| NCT00107354 | Completed | Phase 1 | Cellular Adoptive Immunotherapy in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndromes That Relapsed After Donor Stem Cell Transplant | December 1998 | |
| NCT00107523 | Completed | Phase 1 | Pravastatin, Idarubicin, and Cytarabine in Treating Patients With Acute Myeloid Leukemia | January 2005 | October 2005 |
| NCT00109837 | Completed | Phase 2 | S0333 Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia | April 2005 | November 2014 |
| NCT00112554 | Completed | Phase 3 | Cytarabine With or Without VNP40101M in Treating Patients With Relapsed Acute Myeloid Leukemia | March 2005 | March 2008 |
| NCT00121303 | Completed | Phase 3 | Cytarabine and Daunorubicin With or Without Gemtuzumab Ozogamicin in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes | January 2005 | June 2016 |
| NCT00129168 | Completed | Phase 1/Phase 2 | Zosuquidar in Combination With Daunorubicin and Cytarabine in Patients Ages 55-75 With Newly Diagnosed Acute Myeloid Leukemia (AML) | August 2005 | March 2008 |
| NCT00130195 | Completed | Phase 2 | Study of Imatinib-Combined Chemotherapy for BCR-ABL-Positive Acute Lymphoblastic Leukemia (ALL) | September 2002 | May 2008 |
| NCT00133991 | Completed | Phase 2 | Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Leukemia | July 2005 | August 2013 |
| NCT00137995 | Completed | Phase 3 | R-ICE Versus R-DHAP in Patients Aged 18-65 With Relapse Diffuse Large B-cell Lymphoma | June 2003 | October 2008 |
| NCT00143975 | Completed | Phase 2 | Gemtuzumab Ozogamicin in Combination With A-HAM in Refractory AML (GO-A-HAM) | June 2004 | June 2009 |
| NCT00151242 | Completed | Phase 2/Phase 3 | Study on All-Trans Retinoic Acid, Induction and Consolidation Therapy, and Pegfilgrastim After Consolidation Therapy in Younger Patients With Newly Diagnosed Acute Myeloid Leukemia | July 2004 | August 2013 |
| NCT00151255 | Completed | Phase 3 | All-Trans Retinoic Acid in Combination With Standard Induction and Consolidation Therapy in Older Patients With Newly Diagnosed Acute Myeloid Leukemia | June 2004 | January 2011 |
| NCT00165178 | Completed | Phase 3 | Treatment of Acute Lymphoblastic Leukemia in Children | September 2000 | May 2011 |
| NCT00176462 | Completed | Phase 2 | CINJALL: Treatment for Children With Acute Lymphocytic Leukemia | February 2001 | September 2008 |
| NCT00187122 | Completed | N/A | Treatment for Patients With Stage III or IV Non-Hodgkin Lymphoma | March 1993 | June 2004 |
| NCT00195000 | Completed | Phase 2 | Mylotarg and Ara-C in Untreated Patients Above 60 Years With AML and High-Risk MDS | May 2003 | February 2008 |
| NCT00195104 | Completed | Phase 1/Phase 2 | Arsenic Trioxide in Combination With Cytarabine in Patients With High-risk MDS and Poor-prognosis AML | September 17, 2003 | June 20, 2006 |
| NCT00198978 | Completed | Phase 4 | German Multicenter Trial for Treatment of Elderly Patients With Newly Diagnosed Acute Lymphoblastic Leukemia | January 2003 | June 2014 |
| NCT00198991 | Completed | Phase 4 | German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (07/2003) | April 2003 | June 30, 2013 |
| NCT00199004 | Completed | Phase 4 | Trial for Treatment of Adult Patients With Standard Risk Acute Lymphoblastic Leukemia With Chemotherapy and Rituximab | April 2004 | March 2009 |
| NCT00199017 | Completed | Phase 4 | German Multicenter Trial for the Treatment of Newly Diagnosed T-lymphoblastic Lymphoma in Adults | April 2004 | |
| NCT00199056 | Completed | Phase 4 | German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (06/99) | October 1999 | December 2005 |
| NCT00199069 | Completed | Phase 4 | German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (05/93) | April 1993 | May 2001 |
| NCT00199082 | Completed | Phase 4 | Newly Diagnosed Mature B-ALL, Burkitt's Lymphoma and Other High-grade Lymphoma in Adults | July 2002 | June 2010 |
| NCT00199095 | Completed | Phase 4 | Treatment of Elderly Patients (>65 Years) With Acute Lymphoblastic Leukemia | February 1997 | June 2003 |
| NCT00238368 | Completed | Phase 2 | Fludeoxyglucose F 18 Positron Emission Tomography in Predicting Risk of Relapse in Patients With Non-Hodgkin's Lymphoma Who Are Undergoing Combination Chemotherapy With or Without Autologous Stem Cell or Bone Marrow Transplant | February 2004 | September 17, 2007 |
| NCT00244946 | Completed | Phase 1 | Combination Chemotherapy Followed By Autologous Stem Cell Transplant, and White Blood Cell Infusions in Treating Patients With Non-Hodgkin's Lymphoma | March 2004 | March 2013 |
| NCT00258271 | Completed | Phase 1 | Cladribine, Cytarabine, and Imatinib Mesylate in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Blastic Phase Chronic Myelogenous Leukemia | March 2005 | October 2006 |
| NCT00266136 | Completed | Phase 3 | Biology and Treatment Strategy of AML in Its Subgroups: Multicenter Randomized Trial by the German Acute Myeloid Leukemia Cooperative Group (AMLCG) | June 1999 | October 2012 |
| NCT00268229 | Completed | Phase 1 | Imatinib Mesylate, Daunorubicin, and Cytarabine in Treating Patients With Relapsed Acute Myeloid Leukemia | July 2003 | August 2011 |
| NCT00270881 | Completed | Phase 1/Phase 2 | Safety and Efficacy of Unrelated Cord Blood Transplantation for Adult Patients With Hematologic Malignancies | January 2006 | January 2011 |
| NCT00273884 | Completed | Phase 2 | Amonafide in Combination With Cytarabine in Secondary AML | August 2005 | April 2009 |
| NCT00274807 | Completed | Phase 2 | Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | June 2001 | May 2008 |
| NCT00275015 | Completed | Phase 2 | Cyclophosphamide and Total Body Irradiation in Treating Patients Who Are Undergoing an Autologous Peripheral Stem Cell Transplant For Chronic Lymphocytic Leukemia | January 1998 | April 2012 |
| NCT00276601 | Completed | Phase 2 | Combination Chemotherapy in Treating Patients With Acute Promyelocytic Leukemia | October 2004 | June 2013 |
| NCT00276809 | Completed | Phase 2 | Combination Chemotherapy, Total-Body Irradiation, and Alemtuzumab in Treating Patients Undergoing an Autologous Stem Cell Transplant for Stage I, Stage II, Stage III, or Stage IV Chronic Lymphocytic Leukemia | June 2001 | September 2004 |
| NCT00290498 | Completed | Phase 2 | Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger | August 1, 2005 | August 11, 2017 |
| NCT00295841 | Completed | Phase 1 | Cytarabine and Clofarabine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia | February 2005 | January 7, 2015 |
| NCT00299182 | Completed | Phase 1/Phase 2 | Study of AMG 531 to Evaluate the Safety & Efficacy in Patients With Non-Hodgkin's Lymphoma | March 2006 | April 2012 |
| NCT00302003 | Completed | Phase 3 | Combination Chemotherapy Followed by Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin's Lymphoma | February 2006 | June 30, 2019 |
| NCT00317642 | Completed | Phase 3 | A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I) | August 2006 | January 2012 |
| NCT00337168 | Completed | Phase 2 | S0530 Cytarabine and Clofarabine in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia | October 2006 | January 2013 |
| NCT00345865 | Completed | Phase 2 | Autologous Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma | August 24, 2005 | June 28, 2019 |
| NCT00357305 | Completed | Phase 1 | Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative Disorders | May 2006 | |
| NCT00369317 | Completed | Phase 3 | Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes | March 2007 | December 31, 2021 |
| NCT00372593 | Completed | Phase 3 | Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia | August 2006 | September 30, 2020 |
| NCT00372619 | Completed | Phase 1/Phase 2 | Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia | March 2007 | August 2012 |
| NCT00381680 | Completed | Phase 3 | Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia | March 2007 | |
| NCT00390793 | Completed | Phase 2 | Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia. | September 28, 2006 | February 2, 2024 |
| NCT00392834 | Completed | Phase 2 | Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed, HIV-Associated Burkitt's Lymphoma | September 2006 | July 2013 |
| NCT00400946 | Completed | Phase 3 | Treatment of Acute Lymphoblastic Leukemia in Children | April 2005 | June 2019 |
| NCT00407966 | Completed | Phase 2 | Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | October 2006 | November 2009 |
| NCT00416598 | Completed | Phase 2 | Decitabine as Maintenance Therapy After Standard Therapy in Treating Patients With Previously Untreated Acute Myeloid Leukemia | November 15, 2006 | December 1, 2016 |
| NCT00416819 | Completed | N/A | Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Primary CNS Lymphoma | September 2003 | February 2012 |
| NCT00422591 | Completed | Phase 2 | Standard Idarubicin and Cytarabine for the Treatment of Acute Myeloid Leukemia (AML) | December 2006 | January 2017 |
| NCT00429416 | Completed | Phase 1/Phase 2 | Research Study to Determine if an Experimental Agent, LLME Can Decrease the Incidence and Severity of Graft-Versus-Host-Disease (GVHD) Following Blood (Hematopoietic) Stem Cell Transplantation | March 2004 | May 2009 |
| NCT00430118 | Completed | Phase 3 | Combination Chemotherapy Based on Risk of Relapse in Treating Young Patients With Acute Lymphoblastic Leukemia | July 2000 | January 2012 |
| NCT00439556 | Completed | Phase 2 | Bortezomib and Chemotherapy in Treating Participants With Lymphoid Malignancies Undergoing Stem Cell Transplant | February 13, 2007 | June 7, 2018 |
| NCT00440726 | Completed | Phase 1/Phase 2 | Bortezomib With Chemotherapy for Relapsed Pediatric Acute Lymphoblastic Leukemia (ALL) | August 4, 2006 | February 26, 2011 |
| NCT00450801 | Completed | Phase 2 | R-MACLO-IVAM and Thalidomide in Untreated Mantle Cell Lymphoma | April 2004 | July 2015 |
| NCT00452374 | Completed | Phase 1/Phase 2 | Oxaliplatin, Fludarabine, Cytarabine and Rituximab in Richter's Syndrome, Refractory CLL and PLL | November 2004 | January 2011 |
| NCT00454480 | Completed | Phase 2/Phase 3 | Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes | August 2006 | |
| NCT00469859 | Completed | Phase 1/Phase 2 | Lestaurtinib, Cytarabine, and Idarubicin in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia | June 2007 | March 2010 |
| NCT00470197 | Completed | Phase 1 | Flavopiridol, Cytarabine, and Mitoxantrone in Treating Patients With Relapsed or Refractory Acute Leukemia | April 2007 | |
| NCT00470275 | Completed | Phase 2 | Cytarabine in Treating Young Patients With Recurrent or Refractory Ewing's Sarcoma | May 2007 | December 2013 |
| NCT00472056 | Completed | Phase 2 | Rituximab in Addition to Autologous Transplantation With BEAM for Patients With Lymphoid Malignancies | March 2005 | June 2012 |
| NCT00472849 | Completed | Phase 1/Phase 2 | Oxaliplatin, Fludarabine, Cytarabine, and Rituximab in Patients With Richter's Transformation and Leukemias | May 2007 | February 2012 |
| NCT00477412 | Completed | Phase 1/Phase 2 | Bortezomib, Rituximab and Combination Chemotherapy in Treating Participants With Mantle Cell Lymphoma | April 3, 2007 | October 28, 2020 |
| NCT00480090 | Completed | Phase 2 | A Phase II Study of Ara-C (Cytarabine) in Men With Androgen Independent Prostate Cancer | April 2007 | July 2011 |
| NCT00487448 | Completed | Phase 4 | SMD_FLAG-IDA_98: FLAG-IDA in Induction Treatment of High Risk Myelodysplastic Syndromes or Secondary Acute Myeloblastic Leukemia | July 1998 | June 2007 |
| NCT00488709 | Completed | Phase 4 | Fludarabine, Cytarabine, Topotecan in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | May 2003 | April 2007 |
| NCT00494897 | Completed | Phase 4 | PETHEMA LAL-RI/96: Treatment for Patients With Standard Risk Acute Lymphoblastic Leukemia | June 1996 | December 2007 |
| NCT00505700 | Completed | Phase 1 | VELCADE in Combination With Idarubicin and Cytosine Arabinoside in Patients With Acute Myelogenous Leukemia | July 2003 | |
| NCT00512252 | Completed | Phase 1/Phase 2 | AMD3100 Plus Mitoxantrone, Etoposide and Cytarabine in Acute Myeloid Leukemia | July 2007 | June 2010 |
| NCT00516828 | Completed | Phase 1/Phase 2 | Sorafenib and Low Dose Cytarabine in Older Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | November 27, 2007 | January 10, 2013 |
| NCT00521014 | Completed | Phase 2 | GM-CSF and Rituximab After Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Follicular Non-Hodgkin Lymphoma | October 2007 | July 2013 |
| NCT00528398 | Completed | Phase 2 | Idarubicin and High-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia | September 1994 | December 2015 |
| NCT00540956 | Completed | N/A | Natural Killer Cells in Older Patients With Acute Myeloid Leukemia | November 2006 | |
| NCT00553943 | Completed | Phase 2 | Phase II Study to Evaluate the Combination of Rituximab and DepoCyte® in the C5R Chemotherapy Protocol in Patients Between the Ages of 18 and 60 Years With Primary Cerebral Non-Hodgkin Lymphoma and Systemic Diffuse Large B-cell Lymphoma With Neuromeningeal Invasion at Diagnosis | July 2007 | March 2017 |
| NCT00000658 | Completed | Phase 3 | A Phase III Randomized Trial of Low-Dose Versus Standard-Dose mBACOD Chemotherapy With rGM-CSF for Treatment of AIDS-Associated Non-Hodgkin's Lymphoma | February 1996 | |
| NCT00000689 | Completed | Phase 1 | Phase I Trial of mBACOD and Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in AIDS-Associated Large Cell, Immunoblastic, and Small Non-cleaved Lymphoma | March 1991 | |
| NCT00000703 | Completed | N/A | Chemotherapy and Azidothymidine, With or Without Radiotherapy, for High Grade Lymphoma in AIDS-Risk Group Members | March 1990 | |
| NCT00000801 | Completed | Phase 2 | Phase II Trial of Sequential Chemotherapy and Radiotherapy for AIDS-Related Primary Central Nervous System Lymphoma | April 1998 | |
| NCT00001048 | Completed | Phase 2 | Comparison of Anti HIV Drugs Used Alone or in Combination With Cytosine Arabinoside to Treat Progressive Multifocal Leukoencephalopathy (PML) in HIV-Infected Patients | April 1997 | |
| NCT00002471 | Completed | Phase 2 | Combination Chemotherapy in Treating Patients With Acute B-Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma | February 1990 | January 2003 |
| NCT00002494 | Completed | Phase 2 | Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma or Acute Lymphocytic Leukemia | May 1992 | January 2006 |
| NCT00002502 | Completed | Phase 2 | Combination Chemotherapy and Bone Marrow Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome | July 1992 | May 2000 |
| NCT00002514 | Completed | Phase 3 | Stem Cell Transplantation Compared With Standard Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia in First Remission | May 7, 1993 | |
| NCT00002517 | Completed | Phase 3 | Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome | March 1993 | |
| NCT00002524 | Completed | Phase 2 | Combination Chemotherapy in Treating Patients With AIDS-Related Lymphoma | June 1993 | October 2005 |
| NCT00002534 | Completed | Phase 3 | Bone Marrow Transplantation in Treating Patients With Acute Leukemia in First or Second Remission | May 1993 | April 2003 |
| NCT00002547 | Completed | Phase 2 | Chemotherapy and Bone Marrow Transplantation in Treating Patients Acute Myeloid With Leukemia or Myelodysplastic Syndrome | August 1987 | October 2003 |
| NCT00002552 | Completed | Phase 2 | Chemotherapy Plus Bone Marrow Transplantation in Treating Patients With Refractory Non-Hodgkin's Lymphoma, Hodgkin's Disease, or Multiple Myeloma | October 1993 | October 2003 |
| NCT00002565 | Completed | Phase 3 | Combination Chemotherapy in Treating Patients With Intermediate-Grade or Immunoblastic Non-Hodgkin's Lymphoma | May 25, 1994 | February 5, 2007 |
| NCT00002571 | Completed | Phase 2 | SWOG-9320 Combination Chemotherapy, Radiation Therapy, and Antiviral Therapy in Treating Patients With AIDS-Related Lymphoma | June 1994 | July 2011 |
| NCT00002578 | Completed | Phase 2 | Gallium Nitrate in Treating Patients With AIDS-Related Non-Hodgkin's Lymphoma | August 1994 | |
| NCT00002590 | Completed | Phase 2 | Combination Chemotherapy in Treating Children With Lymphoma | July 1994 | March 2007 |
| NCT00002598 | Completed | Phase 2 | Combination Chemotherapy and Interferon Alfa in Treating Patients With Chronic Myelogenous Leukemia | June 1994 | June 2004 |
| NCT00002609 | Completed | Phase 2 | Monoclonal Antibody Therapy and Chemotherapy in Treating Patients With Acute Promyelocytic Leukemia in Remission | August 1994 | February 2003 |
| NCT00002618 | Completed | Phase 3 | Combination Chemotherapy in Treating Pediatric Patients With Advanced-Stage Large Cell Lymphoma | December 1994 | September 2006 |
| NCT00002638 | Completed | Phase 2 | Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Relapsed Acute Lymphocytic Leukemia | March 1995 | March 2005 |
| NCT00002657 | Completed | Phase 2 | SWOG-9239 Reduction of Immunosuppression Plus Interferon Alfa and Combination Chemotherapy in Treating Patients With Malignant Tumors That Develop After Organ Transplant | May 1995 | July 2011 |
| NCT00002665 | Completed | Phase 2 | SWOG-9400 Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Previously Untreated Acute Lymphocytic Leukemia | July 1995 | December 2003 |
| NCT00002674 | Completed | Phase 2 | Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous Leukemia | October 1994 | March 2000 |
| NCT00002676 | Completed | Phase 2 | Chemotherapy and Whole-Brain Radiation Therapy in Treating Patients With Primary Central Nervous System Non- Hodgkin's Lymphoma | July 1995 | October 2006 |
| NCT00002691 | Completed | Phase 2 | Combination Chemotherapy in Treating Pediatric Patients With Stage III or IV Non-Hodgkin's Lymphoma | August 1995 | June 2000 |
| NCT00002700 | Completed | Phase 3 | Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Acute Lymphoblastic Leukemia | August 1995 | |
| NCT00002718 | Completed | Phase 2 | T-cell Depleted Bone Marrow and G-CSF Stimulated Peripheral Stem Cell Transplantation From Related Donors in Treating Patients With Leukemia, Lymphoblastic Lymphoma, Myelodysplastic Syndrome, or Aplastic Anemia | November 1995 | October 2008 |
| NCT00002719 | Completed | Phase 3 | Combination Chemotherapy With or Without G-CSF in Treating Older Patients With Acute Myeloid Leukemia | December 1995 | |
| NCT00002744 | Completed | Phase 3 | Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Lymphoblastic Leukemia | May 1996 | March 2007 |
| NCT00002756 | Completed | Phase 2 | Induction Intensification in Treating Infants With Newly Diagnosed Acute Lymphoblastic Leukemia | June 1996 | March 2012 |
| NCT00002757 | Completed | Phase 3 | TITLE:Less Intensive Therapy for Children With Non-Hodgkin's Lymphoma | June 2001 | October 2009 |
| NCT00002766 | Completed | Phase 3 | Comparison of Two Combination Chemotherapy Regimens in Treating Adults With Previously Untreated Leukemia or Lymphoma | March 1996 | September 2011 |
| NCT00002768 | Completed | Phase 2 | Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Acute Myeloid Leukemia in Second Remission | June 1996 | March 2009 |
| NCT00002785 | Completed | Phase 2 | Combination Chemotherapy, Bone Marrow Transplantation, and Radiation Therapy in Treating Infants With Acute Lymphoblastic Leukemia | July 1996 | March 2007 |
| NCT00002798 | Completed | Phase 3 | Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic Syndrome | August 1996 | |
| NCT00002800 | Completed | Phase 2 | Chemotherapy in Treating Patients With Newly Diagnosed Acute or Chronic Myelogenous Leukemia or Myelodysplastic Syndrome | July 1996 | March 2003 |
| NCT00002805 | Completed | Phase 2 | Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome | August 1997 | June 2008 |
| NCT00002812 | Completed | Phase 3 | Combination Chemotherapy in Treating Children With Acute Lymphocytic Leukemia | September 1996 | |
| NCT00002816 | Completed | Phase 3 | Combination Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia | December 1996 | April 2006 |
| NCT00002818 | Completed | Phase 1 | High-Dose Cytarabine Plus Deoxycytidine in Treating With Acute Myelogenous Leukemia or Other Hematologic Malignancies | February 1995 | February 2001 |
| NCT00002865 | Completed | Phase 2 | High-Intensity, Brief-Duration Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphocytic Leukemia | April 1995 | August 2001 |
| NCT00002868 | Completed | Phase 3 | Interferon-alfa With or Without Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia | November 20, 1997 | |
| NCT00002945 | Completed | Phase 3 | High Dose Chemotherapy, Peripheral Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Acute Myeloid Leukemia | December 1996 | August 2011 |
| NCT00002970 | Completed | Phase 2 | 506U78 in Treating Patients With Refractory Hematologic Cancer | June 1997 | |
| NCT00002982 | Completed | Phase 2 | Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Older Patients With Refractory or Relapsed Intermediate-Grade Non-Hodgkin's Lymphoma | January 1997 | October 2005 |
| NCT00003061 | Completed | Phase 2 | Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Primary CNS Lymphoma | July 1997 | |
| NCT00003079 | Completed | Phase 1 | Bryostatin 1 and High Dose Cytarabine in Treating Patients With Refractory or Relapsed Leukemia or Lymphoma | September 1997 | May 2001 |
| NCT00003187 | Completed | Phase 2/Phase 3 | Bone Marrow Transplantation in Treating Patients With Leukemia, Myelodysplasia, or Lymphoblastic Lymphoma | May 1995 | February 2005 |
| NCT00003190 | Completed | Phase 3 | Combination Chemotherapy With or Without Valspodar in Treating Patients With Previously Untreated Acute Myeloid Leukemia | January 1998 | |
| NCT00003215 | Completed | Phase 3 | Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Aggressive Non-Hodgkin's Lymphoma | April 1997 | March 2004 |
| NCT00003217 | Completed | Phase 1 | Combination Chemotherapy in Treating Children With Stage III or Stage IV Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia | March 1998 | September 2006 |
| NCT00003239 | Completed | Phase 2 | Chemotherapy and Biological Therapy in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia | March 1998 | October 2001 |
| NCT00003268 | Completed | Phase 1 | Amifostine and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | January 1998 | December 2003 |
| NCT00003311 | Completed | Phase 2 | Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma | May 20, 1998 | April 18, 2007 |
| NCT00003388 | Completed | Phase 2 | Combination Chemotherapy in Treating Patients With AIDS-Related Lymphoma | July 26, 1999 | |
| NCT00003436 | Completed | Phase 3 | Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myeloid Leukemia | July 1998 | December 2005 |
| NCT00003593 | Completed | Phase 3 | Chemotherapy in Treating Children With Down Syndrome and Myeloproliferative Disorder, Acute Myelogenous Leukemia, or Myelodysplastic Syndrome | June 1999 | April 2012 |
| NCT00003619 | Completed | Phase 1/Phase 2 | Combination Chemotherapy Followed By Peripheral Stem Cell Transplantation or Isotretinoin in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Acute Lymphocytic Leukemia | February 1998 | April 2004 |
| NCT00003631 | Completed | Phase 2 | Chemotherapy Plus Radiation Therapy in Treating Patients With Refractory or Relapsed Hodgkin's Lymphoma | August 1998 | |
| NCT00003632 | Completed | Phase 2 | Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Central Nervous System Lymphoma | September 1998 | |
| NCT00003650 | Completed | Phase 3 | Combination Chemotherapy in Treating Children With Non-Hodgkin's Lymphoma | February 1997 | November 2013 |
| NCT00003671 | Completed | Phase 2 | Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Lymphocytic Leukemia | December 1998 | February 2009 |
| NCT00003694 | Completed | Phase 2 | Homoharringtonine Plus Low-Dose Cytarabine in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia in Chronic Phase | March 1999 | |
| NCT00003700 | Completed | Phase 2 | Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia | January 1999 | January 2010 |
| NCT00003783 | Completed | Phase 2 | Combination Chemotherapy in Treating Children With Very High Risk Acute Lymphocytic Leukemia | March 1999 | March 2007 |
| NCT00003934 | Completed | Phase 3 | Tretinoin, Cytarabine, and Daunorubicin Hydrochloride With or Without Arsenic Trioxide Followed by Tretinoin With or Without Mercaptopurine and Methotrexate in Treating Patients With Acute Promyelocytic Leukemia | June 1999 | |
| NCT00003957 | Completed | Phase 2 | Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Relapsed Non-Hodgkin's Lymphoma | December 1998 | August 2001 |
| NCT00004056 | Completed | Phase 1 | Combination Chemotherapy Followed by Melphalan and Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Acute Myeloid Leukemia | October 1999 | March 2007 |
| NCT00004192 | Completed | Phase 2 | Colony-Stimulating Factors to Relieve Neutropenia in Patients With Recurrent Non-Hodgkin's Lymphoma | May 1, 2000 | March 16, 2001 |
| NCT00004215 | Completed | Phase 2 | Leridistim Compared With Filgrastim in Treating Older Patients With Acute Myeloid Leukemia | August 1999 | August 2000 |
| NCT00004217 | Completed | Phase 2 | S9918 PSC 833, Daunorubicin, and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia | February 2000 | March 2006 |
| NCT00004228 | Completed | Phase 3 | Combination Chemotx in Treating Children or Adolescents With Newly Diagnosed Stg III or Stg IV Lymphoblastic Lymphoma | June 2000 | March 31, 2015 |
| NCT00572065 | Completed | Early Phase 1 | Pilot Trial of Arsenic + Cytarabine in Patients With Myelofibrosis | February 29, 2008 | February 8, 2010 |
| NCT00577629 | Completed | Phase 2 | Chemotherapy With Monoclonal Antibody and Radioimmunotherapy for High-Risk B-Cell Non-Hodgkins Lymphoma | June 18, 2005 | November 3, 2016 |
| NCT00591630 | Completed | Phase 2 | Zevalin/BEAM/Rituximab vs BEAM/Rituximab With or Without Rituximab in Autologous Stem Cell Transplantation | November 14, 2007 | March 5, 2020 |
| NCT00602225 | Completed | Phase 1/Phase 2 | Clofarabine, Cytarabine, and G-CSF in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | December 2007 | April 2015 |
| NCT00613457 | Completed | Phase 3 | Combination Chemotherapy Based on Risk of Relapse in Treating Young Patients With Acute Lymphoblastic Leukemia | September 2000 | July 2006 |
| NCT00618501 | Completed | Phase 2 | Imatinib Mesylate and Combination Chemotherapy With or Without a Donor Stem Cell Transplant in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia | October 2005 | January 2009 |
| NCT00620321 | Completed | Phase 2 | A Study of LY2181308 Sodium in Patients With Relapsed or Refractory Acute Myeloid Leukemia | March 2008 | January 2010 |
| NCT00632749 | Completed | Phase 2 | BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment | May 2008 | March 2014 |
| NCT00634244 | Completed | Phase 2 | Comparing Three Different Combination Chemotherapy Regimens in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | October 2008 | October 2014 |
| NCT00656617 | Completed | Phase 2 | Phase II Study of Idarubicin, Cytarabine, and Vorinostat With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) | April 2008 | February 2014 |
| NCT00666588 | Completed | Phase 2 | Bortezomib and Combination Chemotherapy in Treating Younger Patients With Recurrent, Refractory, or Secondary Acute Myeloid Leukemia | April 2008 | December 2012 |
| NCT00669877 | Completed | Phase 2 | Rituximab and Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) for Burkitt's and Burkitt's -Like Leukemia/Lymphoma | August 2002 | October 2015 |
| NCT00671034 | Completed | Phase 3 | Calaspargase Pegol or Pegaspargase and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia | July 21, 2008 | March 31, 2021 |
| NCT00671658 | Completed | Phase 2 | Modified Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) Program for Acute Lymphoblastic Leukemia | November 2002 | July 2013 |
| NCT00691015 | Completed | Phase 2 | Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant | May 2008 | April 2014 |
| NCT00695409 | Completed | Phase 2 | Yttrium-90 Ibritumomab Tiuxetan Plus High-Dose BEAM Followed By ASCT For Relapsed B-Cell Non-Hodgkin Lymphoma | March 18, 2008 | March 27, 2017 |
| NCT00703820 | Completed | Phase 3 | Clofarabine Plus Cytarabine Versus Conventional Induction Therapy And A Study Of NK Cell Transplantation In Newly Diagnosed Acute Myeloid Leukemia | August 4, 2008 | August 14, 2020 |
| NCT00720109 | Completed | Phase 2/Phase 3 | Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia | July 14, 2008 | March 31, 2020 |
| NCT00732498 | Completed | Phase 2 | Rituximab, Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Stage II, III, or IV Follicular NHL | May 15, 2006 | October 15, 2018 |
| NCT00742625 | Completed | Phase 1/Phase 2 | Bortezomib, Daunorubicin, and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia | September 2008 | December 2012 |
| NCT00778375 | Completed | Phase 2 | Clofarabine Plus Low-Dose Cytarabine Induction and Decitabine Consolidation in Frontline Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS) | October 2008 | January 2015 |
| NCT00788892 | Completed | Phase 2 | Trial of CPX-351 in Newly Diagnosed Elderly AML Patients | October 2008 | December 2011 |
| NCT00795002 | Completed | Phase 2 | Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | November 2008 | September 2012 |
| NCT00804856 | Completed | Phase 2 | Phase I/IIa Trial to Investigate BI 6727 (Volasertib) as Monotherapy or in Combination With Cytarabine in Acute Myeloid Leukaemia | November 27, 2008 | April 23, 2021 |
| NCT00831766 | Completed | Phase 1/Phase 2 | Idarubicin + Cytarabine and Lenalidomide in Patients With Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML) | June 25, 2009 | November 16, 2020 |
| NCT00839982 | Completed | Phase 1/Phase 2 | Clofarabine and Cytarabine in Treating Older Patients With AML or High-Risk MDS | November 2008 | December 2012 |
| NCT00840177 | Completed | Phase 2 | S0919 Idarubicin, Cytarabine, and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia | December 10, 2009 | October 21, 2021 |
| NCT00840684 | Completed | Phase 1/Phase 2 | Laromustine, Daunorubicin, and Cytarabine in Treating Patients With Acute Myeloid Leukemia | January 2009 | |
| NCT00850382 | Completed | Phase 1/Phase 2 | Dasatinib (Sprycel™) in Patients With Newly Diagnosed Core Binding Factor (CBF) Acute Myeloid Leukemia (AML) | June 2009 | November 2015 |
| NCT00853008 | Completed | Phase 4 | Treatment of High Risk Adult Acute Lymphoblastic Leukemia | January 2003 | December 2012 |
| NCT00866307 | Completed | Phase 1 | Pegaspargase and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia (Closed to Accrual 4-22-2011) | February 23, 2009 | March 31, 2021 |
| NCT00866749 | Completed | Phase 2 | Augmented Berlin-Frankfurt-Munster (BFM) Therapy for Adolescent/Young Adults With Acute Lymphoblastic Leukemia or Acute Lymphoblastic Lymphoma | September 12, 2006 | July 26, 2018 |
| NCT00866918 | Completed | Phase 3 | Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia | March 9, 2009 | September 30, 2022 |
| NCT00873093 | Completed | Phase 2 | Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma | March 2009 | September 2014 |
| NCT00906945 | Completed | Phase 1/Phase 2 | Chemosensitization With Plerixafor Plus G-CSF in Acute Myeloid Leukemia | February 2011 | September 2015 |
| NCT00908167 | Completed | Phase 1 | Sorafenib in Combination With Cytarabine and Clofarabine in Patients With Refractory or Relapsed Hematologic Malignancies | September 2009 | June 2015 |
| NCT00945815 | Completed | Phase 2 | S0910 Epratuzumab, Cytarabine, and Clofarabine in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia | September 2010 | August 2017 |
| NCT00968760 | Completed | Phase 1 | CD19-specific T Cell Infusion in Patients With B-Lineage Lymphoid Malignancies | June 20, 2011 | April 23, 2020 |
| NCT00973752 | Completed | Phase 2 | Treatment of Older Adults With Acute Lymphoblastic Leukemia | August 2009 | April 2016 |
| NCT00992446 | Completed | Phase 2 | Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma | September 2, 2010 | October 29, 2019 |
| NCT01004497 | Completed | Phase 2 | First-line Dasatinib Plus Conventional Chemotherapy in Adults With Newly Diagnosed Ph-Positive ALL | March 2010 | April 2015 |
| NCT01008462 | Completed | Phase 2 | Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia | March 18, 2010 | June 30, 2018 |
| NCT01019317 | Completed | Phase 2 | Fludarabine and Cytarabine in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS) | November 2009 | September 2012 |
| NCT01025154 | Completed | Phase 2 | Clofarabine, Idarubicin, and Cytarabine Combination in Acute Myeloid Leukemia (AML) Induction | January 2010 | February 2013 |
| NCT01031368 | Completed | Phase 1 | Clofarabine, Cytarabine, and Filgrastim Followed by Infusion of Non-HLA Matched Ex Vivo Expanded Cord Blood Progenitors in Treating Patients With Acute Myeloid Leukemia | December 2009 | October 24, 2012 |
| NCT01035463 | Completed | Phase 1/Phase 2 | Lenalidomide Therapy After Chemotherapy & Stem Cell Transplant in Treating Chemotherapy Resistan Non-Hodgkin Lymphoma | November 12, 2009 | July 27, 2018 |
| NCT01101880 | Completed | Phase 2 | Clofarabine, Cytarabine, and Filgrastim in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia, Advanced Myelodysplastic Syndrome, and/or Advanced Myeloproliferative Neoplasm | August 2010 | July 2017 |
| NCT01117441 | Completed | Phase 3 | International Collaborative Treatment Protocol For Children And Adolescents With Acute Lymphoblastic Leukemia | June 2010 | December 31, 2021 |
| NCT01127009 | Completed | Phase 1 | Bortezomib, Mitoxantrone, Etoposide, and Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia | July 2010 | May 2014 |
| NCT01130506 | Completed | Phase 1 | Decitabine, Vorinostat, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome | May 17, 2010 | |
| NCT01132586 | Completed | Phase 1 | Lenalidomide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia | May 2010 | January 2014 |
| NCT01141712 | Completed | Phase 2 | Autologous Transplant in HIV Patients (BMT CTN 0803) | April 2010 | June 2016 |
| NCT01154439 | Completed | Phase 1 | Everolimus MICE-regimen in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia | October 2010 | September 15, 2015 |
| NCT01156883 | Completed | N/A | Combination Chemotherapy in Treating Young Adult Patients With Acute Lymphoblastic Leukemia | April 2010 | October 31, 2017 |
| NCT01161550 | Completed | Phase 1 | Cladribine Based Induction Therapy With All-Trans Retinoic Acid and Midostaurin in Relapsed/Refractory AML | November 2010 | August 2012 |
| NCT01174888 | Completed | Phase 1 | Phase I Combination of Midostaurin, Bortezomib, and Chemo in Relapsed/Refractory Acute Myeloid Leukemia | August 2010 | May 2016 |
| NCT01180322 | Completed | Phase 2 | Trial Evaluating Induction Therapy With Idarubicin and Etoposide Plus Sequential or Concurrent Azacitidine and Maintenance Therapy With Azacitidine | November 2010 | October 2, 2016 |
| NCT01184898 | Completed | N/A | Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML) | July 2010 | February 2016 |
| NCT01225874 | Completed | N/A | Biomarkers to Classify Young Patients With Acute Lymphoblastic Leukemia (ALL) and Remission Induction Therapy in Young Patients With B-Precursor ALL | December 1999 | |
| NCT01230983 | Completed | Phase 3 | Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia or Advanced Lymphoblastic Non-Hodgkin's Lymphoma | June 1996 | October 2004 |
| NCT01237808 | Completed | Phase 3 | Study of Low-Dose Cytarabine and Etoposide With or Without All-Trans Retinoic Acid in Older Patients Not Eligible for Intensive Chemotherapy With Acute Myeloid Leukemia and NPM1 Mutation | March 2011 | July 13, 2018 |
| NCT01238211 | Completed | Phase 2 | Combination Chemotherapy and Dasatinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | December 14, 2010 | March 15, 2021 |
| NCT01246622 | Completed | Phase 1 | Lenalidomide and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | February 7, 2011 | June 5, 2019 |
| NCT01249430 | Completed | Phase 1 | Azacitidine in Combination With Mitoxantrone, Etoposide Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | January 20, 2011 | May 24, 2013 |
| NCT01253070 | Completed | Phase 2 | Sorafenib Tosylate and Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia | April 1, 2011 | April 15, 2021 |
| NCT01256398 | Completed | Phase 2 | Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia | December 14, 2010 | November 15, 2021 |
| NCT01272245 | Completed | Phase 2 | Omacetaxine and Low Dose Cytarabine in Older Patients With Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS) | July 2011 | January 2017 |
| NCT01289457 | Completed | Phase 1/Phase 2 | Clofarabine, Idarubicin, and Cytarabine (CIA) Versus Fludarabine, Idarubicin, and Cytarabine (FLAI) in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome | February 2, 2011 | June 28, 2017 |
| NCT01321346 | Completed | Phase 1 | A Study Of Panobinostat In Children With Refractory Hematologic Malignancies | March 2011 | |
| NCT01324063 | Completed | Phase 3 | A Randomized Phase III Study of Intensive Consolidation With High Dose Cytosine Arabinoside in Acute Myelogenous Leukemia (AML-8B) | November 1986 | |
| NCT01349972 | Completed | Phase 2 | Alvocidib, Cytarabine, and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | April 2011 | May 2014 |
| NCT01358253 | Completed | Phase 4 | Rituximab Plus Chemotherapy for CD20+ Adult Acute Lymphoblastic Leukemia | December 2010 | December 2012 |
| NCT01363128 | Completed | Phase 2 | Combination Chemotherapy and Ofatumumab in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma | July 12, 2011 | April 8, 2020 |
| NCT01390337 | Completed | Phase 1 | A Study to Assess AC220 Given in Combination With Induction and Consolidation Therapy in Newly Diagnosed Acute Myeloid Leukemia (AML) | October 2011 | February 2015 |
| NCT01399372 | Completed | Phase 2 | Rituximab, Methotrexate, Vincristine Sulfate, Procarbazine Hydrochloride, and Cytarabine With or Without Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma | September 2011 | May 20, 2022 |
| NCT01411267 | Completed | Phase 1 | AC220 for Children With Relapsed/Refractory ALL or AML | September 1, 2011 | September 12, 2013 |
| NCT01412879 | Completed | Phase 2 | S1106 Rituximab With Combination Chemotherapy or Bendamustine Hydrochloride Followed by Consolidation Chemotherapy and Stem Cell Transplantation in Older Patients With Previously Untreated Mantle Cell Lymphoma | November 2011 | March 2021 |
| NCT01435343 | Completed | Phase 1/Phase 2 | Treatment of Relapsed or Refractory Acute Myeloblastic Leukemia | July 2012 | December 2016 |
| NCT01444742 | Completed | Phase 2 | Clofarabine Plus Low-Dose Cytarabine for Patients With Higher-Risk Myelodysplastic Syndrome (MDS) | November 16, 2011 | January 29, 2017 |
| NCT01451515 | Completed | Phase 2 | NHL16: Study For Newly Diagnosed Patients With Acute Lymphoblastic Lymphoma | May 25, 2012 | May 31, 2022 |
| NCT01463046 | Completed | Phase 1 | Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome | January 2012 | December 2018 |
| NCT01477606 | Completed | Phase 2 | Protocol in Acute Myeloid Leukemia With FLT3-ITD | May 2012 | February 26, 2020 |
| NCT01481272 | Completed | Phase 2 | Ofatumumab With IVAC Salvage Chemotherapy in Diffuse Large B Cell Lymphoma Patients | November 2011 | December 2018 |
| NCT01497002 | Completed | Phase 3 | Comparison of the OSHO Protocol to a Standard Arm Protocol of the German AML Intergroup in Patients With AML>60a | April 2005 | July 18, 2018 |
| NCT01527149 | Completed | Phase 2 | Ofatumumab in Combination With Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine Sulfate, and Dexamethasone Alternating With Ofatumumab in Combination With Cytarabine and Methotrexate in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma | December 6, 2011 | January 11, 2024 |
| NCT01546038 | Completed | Phase 2 | A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome | June 27, 2012 | March 4, 2019 |
| NCT01555268 | Completed | Phase 1 | Trebananib With or Without Low-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia | October 31, 2011 | August 3, 2016 |
| NCT01555541 | Completed | Phase 2 | Intensive Consolidation and Stem Cell Mobilization Therapy Followed by Autologous Stem Cell Transplantation in High-risk Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma | May 25, 2012 | July 1, 2021 |
| NCT01567059 | Completed | Phase 2 | Tosedostat in Combination With Cytarabine or Decitabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | May 2012 | June 2013 |
| NCT01614197 | Completed | Phase 1 | A Trial of Temsirolimus With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma | July 3, 2015 | September 4, 2020 |
| NCT01635296 | Completed | Phase 1 | A Study of RO5045337 in Combination With Cytarabine in Patients With Acute Myelogenous Leukemia | July 2012 | October 2013 |
| NCT01641250 | Completed | Phase 1 | A Study of RO5429083 Alone or in Combination With Cytarabine in Patients With Acute Myelogenous Leukemia | August 2012 | February 2015 |
| NCT01656031 | Completed | Phase 2 | A Phase II Open-Label Study of High-Dose Cytarabine and Clofarabine in Adult Patients With Refractory or Relapsed Acute Myelogenous Leukemia or Refractory or Relapsed Acute Lymphoblastic Leukemia | February 2005 | November 2008 |
| NCT01681537 | Completed | Phase 1 | Lenalidomide Plus Chemotherapy for AML | September 2012 | December 2015 |
| NCT01690507 | Completed | Phase 1/Phase 2 | Decitabine Combining Modified CAG Followed by HLA Haploidentical Peripheral Blood Mononuclear Cells Infusion for Elderly Patients With Acute Myeloid Leukemia(AML） | November 2012 | January 2016 |
| NCT01692197 | Completed | Phase 2 | E7070, Idarubicin and Cytarabine in Relapsed AML and High-Risk Myelodysplastic Syndromes | February 1, 2013 | June 7, 2017 |
| NCT01700946 | Completed | Phase 2 | Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma | April 15, 2013 | July 24, 2021 |
| NCT01721876 | Completed | Phase 3 | Volasertib in Combination With Low-dose Cytarabine in Patients Aged 65 Years and Above With Previously Untreated Acute Myeloid Leukaemia, Who Are Ineligible for Intensive Remission Induction Therapy (POLO-AML-2) | January 29, 2013 | May 28, 2021 |
| NCT01729845 | Completed | Phase 1/Phase 2 | Decitabine Followed by Mitoxantrone Hydrochloride, Etoposide, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes | December 20, 2012 | April 3, 2017 |
| NCT01768897 | Completed | Phase 1 | CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | January 2013 | January 2016 |
| NCT01769209 | Completed | Phase 2 | Bortezomib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia | March 2013 | July 4, 2017 |
| NCT01773408 | Completed | Phase 1 | A Study of RO5503781 as a Single Agent or in Combination With Cytarabine in Participants With Acute Myelogenous Leukemia | February 2013 | June 2016 |
| NCT01779843 | Completed | Phase 1 | Alisertib for Acute Myeloid Leukemia | April 2013 | November 2016 |
| NCT01787474 | Completed | Phase 1 | Donor Natural Killer Cells in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | May 19, 2014 | June 17, 2021 |
| NCT01794702 | Completed | Phase 1/Phase 2 | Decitabine Followed by Clofarabine, Idarubicin, and Cytarabine in Acute Leukemia | February 20, 2013 | January 11, 2018 |
| NCT01802333 | Completed | Phase 3 | Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia | February 12, 2013 | June 15, 2017 |
| NCT01806571 | Completed | Phase 2 | Daunorubicin Hydrochloride, Cytarabine, and Nilotinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | March 12, 2015 | November 30, 2019 |
| NCT01822015 | Completed | Early Phase 1 | Sirolimus, Idarubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | March 15, 2013 | December 12, 2019 |
| NCT01830777 | Completed | Phase 1 | Brentuximab Vedotin + Re-induction Chemotherapy for AML | May 2013 | May 2019 |
| NCT01831232 | Completed | N/A | Idarubicin, Cytarabine, and Pravastatin Sodium in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes | May 2013 | January 2016 |
| NCT01839240 | Completed | Phase 1 | Azacitidine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With High-Risk Acute Myeloid Leukemia | June 6, 2012 | August 16, 2019 |
| NCT01861002 | Completed | Phase 1 | A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML | May 22, 2013 | July 28, 2014 |
| NCT01870596 | Completed | Phase 2 | Cytarabine With or Without SCH 900776 in Treating Adult Patients With Relapsed Acute Myeloid Leukemia | May 2013 | December 2014 |
| NCT01890746 | Completed | Phase 2 | A Safety and Efficacy Study of Eltrombopag in Subjects With AML | September 5, 2013 | January 25, 2017 |
| NCT01892371 | Completed | Phase 1/Phase 2 | Quizartinib With Azacitidine or Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome | November 12, 2013 | February 7, 2023 |
| NCT01921387 | Completed | Phase 1/Phase 2 | Radiolabeled Monoclonal Antibody and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With High-Risk Lymphoid Malignancies | October 9, 2013 | July 26, 2020 |
| NCT01969435 | Completed | Phase 2 | Study of Melphalan HCl for Injection (Propylene Glycol-free), Carmustine, Etoposide, Cytarabine (BEAM Regimen) and Autologous Stem Cell Transplantation for Lymphoma | March 19, 2014 | May 31, 2017 |
| NCT01979536 | Completed | Phase 2 | Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma | November 13, 2013 | March 31, 2024 |
| NCT01999413 | Completed | Phase 2 | Pilot Study Efficacy and Tolerance Fish Oil Emulsion Daunorubicin and Cytarabine Treatment of AML Younger Patients | November 2013 | April 2018 |
| NCT02013648 | Completed | Phase 3 | Randomized Phase III Study of Intensive Chemotherapy With or Without Dasatinib (Sprycel™) | July 2014 | February 2024 |
| NCT02029950 | Completed | Phase 1 | Pomalidomide After Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | December 16, 2013 | May 13, 2020 |
| NCT02038777 | Completed | Phase 1 | A Study Of PF-04449913 In Japanese Patients With Select Hematologic Malignancies | March 25, 2014 | December 28, 2023 |
| NCT02044796 | Completed | Phase 1/Phase 2 | Filgrastim, Cladribine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes | January 23, 2014 | April 16, 2018 |
| NCT02046122 | Completed | Phase 1/Phase 2 | Adoptive Transfer of Haplo-identical DLI for AML and MDS | July 2014 | July 31, 2019 |
| NCT02059239 | Completed | Phase 1/Phase 2 | Bendamustine Bridge to Autologous or Allogeneic Transplant for Relapsed/Refractory Lymphoma | June 4, 2014 | June 15, 2020 |
| NCT02070458 | Completed | Phase 1 | Ixazomib, Mitoxantrone Hydrochloride, Etoposide, and Intermediate-Dose Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia | October 8, 2014 | August 15, 2017 |
| NCT02121418 | Completed | N/A | Decitabine and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia, High Risk Myelodysplastic Syndrome, or Myeloproliferative Neoplasm | June 2014 | February 14, 2018 |
| NCT02130869 | Completed | Phase 1 | A Pilot Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+ Positively-Selected Autologous Hematopoietic Stem Cells in Children With High Risk Solid Tumors or Lymphomas | October 10, 2014 | December 20, 2017 |
| NCT02135874 | Completed | Phase 2 | Clofarabine, Idarubicin, Cytarabine, Vincristine Sulfate, and Dexamethasone in Treating Patients With Newly Diagnosed or Relapsed Mixed Phenotype Acute Leukemia | October 27, 2014 | February 21, 2023 |
| NCT02144675 | Completed | Phase 2 | Choline Magnesium Trisalicylate and Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia | January 2009 | April 26, 2016 |
| NCT02212561 | Completed | Phase 1 | Selinexor With Fludarabine and Cytarabine for Treatment of Refractory or Relapsed Leukemia or Myelodysplastic Syndrome | August 2014 | December 2015 |
| NCT02228772 | Completed | Phase 1 | Phase I Study of MLN 9708 in Addition to Chemotherapy for the Treatment of Acute Lymphoblastic Leukemia in Older Adults | December 2014 | November 2019 |
| NCT02236013 | Completed | Phase 1 | A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia | January 7, 2015 | July 26, 2021 |
| NCT02249091 | Completed | Phase 2 | A Phase II Study of Selinexor Plus Cytarabine and Idarubicin in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) | September 2014 | July 31, 2018 |
| NCT02280525 | Completed | Phase 1 | Cord Blood Natural Killer (NK) Cells in Leukemia/Lymphoma | March 5, 2015 | July 9, 2019 |
| NCT02283177 | Completed | Phase 2 | A Safety and Tolerability Study of Crenolanib in Combination With Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia Patients With FLT3 Mutations | January 2015 | December 2019 |
| NCT02287233 | Completed | Phase 1/Phase 2 | A Study Evaluating Venetoclax in Combination With Low-Dose Cytarabine in Treatment-Naïve Participants With Acute Myelogenous Leukemia | December 31, 2014 | August 10, 2021 |
| NCT02293109 | Completed | Phase 1 | Carfilzomib and Hyper-CVAD in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoma | December 17, 2015 | January 11, 2018 |
| NCT02299518 | Completed | Phase 1 | Selinexor and Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | May 18, 2015 | March 6, 2018 |
| NCT02306291 | Completed | Phase 1/Phase 2 | Study to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination With Chemotherapy in AML | March 2015 | May 2018 |
| NCT02319135 | Completed | Phase 3 | Azacytidine (Vidaza®) Versus Fludarabine and Cytarabine (Fluga Scheme) in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia | October 2014 | October 28, 2019 |
| NCT02323607 | Completed | Phase 1 | Pacritinib and Chemotherapy in Treating Patients With Acute Myeloid Leukemia and FLT3 Mutations | January 12, 2016 | July 12, 2018 |
| NCT02400281 | Completed | Phase 1/Phase 2 | Study of Crenolanib Combined With Chemotherapy in FLT3-mutated Acute Myeloid Leukemia Patients | September 2015 | July 15, 2020 |
| NCT02403310 | Completed | Phase 1 | A Study of Selinexor in Combination With Daunorubicin and Cytarabine for Untreated AML | June 18, 2015 | February 1, 2021 |
| NCT02416908 | Completed | Phase 1/Phase 2 | Study of CLAG + Selinexor in Relapsed or Refractory Acute Myeloid Leukemia | June 16, 2015 | June 21, 2019 |
| NCT02441803 | Completed | Phase 2 | Allogeneic Hematopoietic Stem Cell Transplantation (AlloSCT) Initial Salvage Therapy for Induction Failure Acute Myeloid Leukemia (AML) | September 14, 2015 | September 22, 2021 |
| NCT02464657 | Completed | Phase 1/Phase 2 | Study of Idarubicin, Cytarabine, and Nivolumab in Patients With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) | July 2015 | May 7, 2020 |
| NCT02484391 | Completed | Phase 1 | CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Granulocytic Sarcoma | September 2015 | February 2, 2022 |
| NCT02504359 | Completed | Phase 1 | Combination Chemotherapy and Donor Stem Cell Transplant Followed by Ixazomib Citrate Maintenance Therapy in Treating Patients With Relapsed High-Risk Multiple Myeloma | July 20, 2015 | September 9, 2020 |
| NCT02523976 | Completed | Phase 2 | Dasatinib Combined With Chemotherapy in Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia | August 1, 2015 | December 31, 2021 |
| NCT02560025 | Completed | Phase 2 | Phase II Trial of Alisertib With Induction Chemotherapy in High-risk AML | December 2015 | December 2018 |
| NCT02573363 | Completed | Phase 1 | Selinexor With Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia | October 7, 2015 | May 3, 2019 |
| NCT02582359 | Completed | Phase 1 | MLN 9708 in Induction and Consolidation for Adults With AML >= 60 Years of Age | January 2016 | April 2022 |
| NCT02583893 | Completed | Phase 2 | Biomarkers in Predicting Treatment Response to Sirolimus and Chemotherapy in Patients With High-Risk Acute Myeloid Leukemia | October 7, 2015 | May 17, 2023 |
| NCT02626338 | Completed | Phase 1/Phase 2 | Pilot Study of Crenolanib Combined With Standard Salvage Chemotherapy in Subjects With R/R AML | February 2016 | February 2018 |
| NCT02642965 | Completed | Phase 1/Phase 2 | Liposome-encapsulated Daunorubicin-Cytarabine, Fludarabine Phosphate, Cytarabine, and Filgrastim in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia | May 2, 2016 | June 30, 2023 |
| NCT02649764 | Completed | Phase 1 | Prexasertib (LY2606368), Cytarabine, and Fludarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | May 4, 2016 | July 12, 2022 |
| NCT02652871 | Completed | Phase 1 | LY2510924, Idarubicin and Cytarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia | May 9, 2016 | July 16, 2019 |
| NCT02666950 | Completed | Phase 2 | WEE1 Inhibitor AZD1775 With or Without Cytarabine in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome | May 5, 2017 | October 17, 2018 |
| NCT02719574 | Completed | Phase 1/Phase 2 | Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 Mutation | April 2016 | January 24, 2024 |
| NCT02728050 | Completed | Phase 1/Phase 2 | Filgrastim, Cladribine, Cytarabine, and Mitoxantrone With Sorafenib in Treating Patients With Newly-Diagnosed, Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | December 1, 2016 | April 4, 2023 |
| NCT02728531 | Completed | Phase 1 | Bendamustine and Rituximab Alternating With Cytarabine and Rituximab for Untreated Mantle Cell Lymphoma | April 18, 2016 | August 16, 2023 |
| NCT02741388 | Completed | Phase 1 | A Phase Ib Study of Oral Selinexor in Adult Patients With Relapsed/Refractory B-cell Lymphoma Receiving R-DHAOx or R-GDP | October 2016 | September 29, 2021 |
| NCT02756572 | Completed | Phase 2 | Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myeloid Neoplasms | September 22, 2016 | July 1, 2020 |
| NCT02779283 | Completed | Phase 1 | Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia | January 13, 2016 | September 20, 2018 |
| NCT02834390 | Completed | Phase 1 | Study of Quizartinib in Japanese Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) | August 12, 2016 | October 19, 2017 |
| NCT02835729 | Completed | Phase 1 | A Study of Indoximod in Combination With (7+3) Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia | July 2016 | December 27, 2019 |
| NCT02873338 | Completed | Phase 2 | Dociparstat Sodium (CX-01) Combined With Standard Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia | August 2016 | June 2019 |
| NCT02921061 | Completed | Phase 1/Phase 2 | Decitabine With GCLAM for Adults With Newly Diagnosed, Relapsed, or Refractory AML or High-Risk MDS | November 17, 2016 | October 24, 2018 |
| NCT02930109 | Completed | Phase 1/Phase 2 | A Study of PTX-200 (Triciribine) Plus Cytarabine in Refractory or Relapsed Acute Leukemia | December 9, 2016 | March 4, 2024 |
| NCT02971397 | Completed | Phase 1 | Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | November 2016 | August 8, 2018 |
| NCT03012672 | Completed | Phase 2 | Higher or Lower Dose Cladribine, Cytarabine, and Mitoxantrone in Treating Medically Less Fit Patients With Newly Diagnosed Acute Myeloid Leukemia or Myeloid Neoplasm | December 30, 2016 | February 26, 2021 |
| NCT03019640 | Completed | Phase 2 | Umbilical Cord Blood NK Cells, Rituximab, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma | October 10, 2017 | August 16, 2021 |
| NCT03072771 | Completed | Phase 1 | Blinatumomab Consolidation Post Autologous Stem Cell Transplantation in Patients With Diffuse Large B-Cell Lymphoma (DLBCL) | August 1, 2017 | October 30, 2023 |
| NCT03118466 | Completed | Phase 2 | Mitoxantrone, Etoposide, and Cytarabine (MEC) Plus Lenalidomide for Relapsed or Refractory Acute Myeloid Leukemia | September 25, 2017 | August 18, 2021 |
| NCT03194932 | Completed | Phase 1 | Study of Venetoclax in Combination With Chemotherapy in Pediatric Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Leukemia of Ambiguous Lineage | July 11, 2017 | June 22, 2022 |
| NCT03263936 | Completed | Phase 1 | Epigenetic Reprogramming in Relapse/Refractory AML | July 11, 2017 | February 10, 2022 |
| NCT03298984 | Completed | Phase 1 | Ph I Study of Alvocidib and Cytarabine/Daunorubicin (7+3) in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML). | September 25, 2017 | March 20, 2020 |
| NCT03303339 | Completed | Phase 1/Phase 2 | Onvansertib in Combination With Either Low-dose Cytarabine or Decitabine in Adult Patients With Acute Myeloid Leukemia (AML) | November 17, 2017 | November 17, 2021 |
| NCT03349281 | Completed | Phase 1 | Pevonedistat With VXLD Chemotherapy for Adolescent/Young Adults With Relapsed/Refractory ALL or Lymphoblastic NHL | March 25, 2019 | October 12, 2022 |
| NCT03379727 | Completed | Phase 3 | Study to Assess the Safety and Efficacy of Midostaurin (PKC412) in Combination With Standard Chemotherapy During Induction and Consolidation Followed by 12 Months of Maintenance Monotherapy in Patients With Newly-diagnosed FMS-like Tyrosine 3 (FLT3) Kinase Receptor-mutated Acute Myeloid Leukemia. | February 13, 2018 | July 9, 2021 |
| NCT03384654 | Completed | Phase 2 | A Study to Evaluate the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Participants Greater Than or Equal to (>=)1 and Less Than or Equal to (<=) 30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma | May 14, 2018 | September 27, 2022 |
| NCT03416179 | Completed | Phase 3 | A Study Evaluating Intensive Chemotherapy With or Without Glasdegib or Azacitidine With or Without Glasdegib In Patients With Previously Untreated Acute Myeloid Leukemia | April 20, 2018 | January 17, 2022 |
| NCT03441048 | Completed | Phase 1 | Lintuzumab-Ac225 in Combination With Cladribine + Cytarabine + Filgastrim + Mitoxantrone (CLAG-M) for Relapsed/Refractory Acute Myeloid Leukemia | May 22, 2018 | May 22, 2024 |
| NCT03459859 | Completed | Phase 1 | Pevonedistat and Low Dose Cytarabine in Adult Patients With AML and MDS | May 21, 2018 | June 25, 2021 |
| NCT03531918 | Completed | Phase 1/Phase 2 | Gemtuzumab Ozogamicin With G-CSF, Cladribine, Cytarabine & Mitoxantrone for Untreated AML & High-Grade Myeloid Neoplasm | September 14, 2018 | November 1, 2021 |
| NCT03563560 | Completed | Phase 1 | A Study of DSP-2033 (Alvocidib) in Patients With Acute Myeloid Leukemia | May 15, 2018 | March 31, 2020 |
| NCT03654716 | Completed | Phase 1 | Phase 1 Study of the Dual MDM2/MDMX Inhibitor ALRN-6924 in Pediatric Cancer | November 1, 2018 | July 17, 2023 |
| NCT03661515 | Completed | Phase 1 | Selinexor (KPT-330) Plus FLAG-Ida for the Treatment of Relapsing/Refractory AML | July 17, 2018 | October 15, 2019 |
| NCT03813147 | Completed | Phase 1 | Pevonedistat, Azacitidine, Fludarabine Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome | May 17, 2019 | December 31, 2023 |
| NCT04509622 | Completed | Phase 3 | A Study of Oral Venetoclax Tablet in Combination With Subcutaneous Low-Dose Cytarabine (LDAC) Injection to Assess Adverse Events in Adult Japanese Participants With Acute Myeloid Leukemia (AML) | October 5, 2020 | April 15, 2021 |
| NCT04752163 | Completed | Phase 1/Phase 2 | DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia | March 25, 2021 | November 8, 2023 |
| NCT04778410 | Completed | Phase 2 | Study of Magrolimab Combinations in Participants With Myeloid Malignancies | June 28, 2021 | March 1, 2024 |
| NCT00423826 | No longer available | Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease | January 2007 | January 2015 | |
| NCT05863845 | Not yet recruiting | N/A | Efficacy and Safety of Venetoclax Combined With BEAM Pretreatment in Autologous Transplantation for DLBCL | June 1, 2023 | November 30, 2025 |
| NCT05805072 | Not yet recruiting | N/A | Selinexor and HAAG With/Without HMA in Relapsed/Refractory Acute Leukemia (AML) Patients | May 1, 2023 | June 30, 2024 |
| NCT06387121 | Not yet recruiting | Phase 2 | Efficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Elderly/Unfit Ph- B-ALL | April 15, 2024 | December 31, 2028 |
| NCT06289673 | Not yet recruiting | Phase 4 | Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma | July 2024 | May 2039 |
| NCT05766514 | Not yet recruiting | Phase 2 | Trial of Cladribine and Low-Dose Cytarabine (LoDAC) Alternating With Decitabine vs. Hypomethylating Agents (HMA) Plus Venetoclax as Frontline Therapy for AML or High-Grade MDS in Patients Unfit for Intensive Induction | June 2024 | December 2030 |
| NCT06451861 | Not yet recruiting | Phase 2 | Randomized Study of ABC-14 Regimen Compared With "3+7" Standard Induction Therapy or AB-14 for ND AML | May 31, 2024 | June 30, 2027 |
| NCT06247787 | Not yet recruiting | Phase 1 | A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy | July 12, 2024 | April 1, 2026 |
| NCT05554393 | Not yet recruiting | Phase 2 | Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial) | May 30, 2024 | December 31, 2025 |
| NCT06376162 | Not yet recruiting | Phase 1 | Ziftomenib in Combination With Chemotherapy for Children With Relapsed/Refractory Acute Leukemia | June 2024 | August 2027 |
| NCT04945096 | Not yet recruiting | Phase 3 | Outcomes of Patients After Allo-HSCT With Decitabine and NAC | July 1, 2021 | December 1, 2025 |
| NCT05751044 | Not yet recruiting | Phase 1/Phase 2 | HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies | October 1, 2023 | October 1, 2030 |
| NCT05745714 | Not yet recruiting | Phase 1/Phase 2 | HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies | October 1, 2023 | October 1, 2030 |
| NCT06377540 | Not yet recruiting | Phase 2 | MT2022-60: Ph 2 Study of Pembro+ BEAM With ASCT for Relapsed Hodgkin Lymphoma | August 1, 2024 | September 1, 2027 |
| NCT05628623 | Not yet recruiting | Phase 2 | Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia (AML) Following Initial Treatment | October 23, 2023 | February 2027 |
| NCT06317662 | Not yet recruiting | Phase 2 | Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia | July 31, 2024 | December 21, 2027 |
| NCT06175702 | Not yet recruiting | Treatment Protocol for Newky Diagnosed Adult Ph Positive ALL | December 25, 2023 | December 25, 2030 | |
| NCT06313437 | Not yet recruiting | Phase 1 | Revumenib in Combination With 7+3 + Midostaurin in AML | September 2024 | March 2, 2027 |
| NCT05521087 | Not yet recruiting | Phase 1 | A Study of JNJ-75276617 in Combination With Conventional Chemotherapy for Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias | December 26, 2025 | January 29, 2030 |
| NCT06390319 | Not yet recruiting | Phase 2 | Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL) | June 2024 | December 2033 |
| NCT05658640 | Not yet recruiting | Phase 1/Phase 2 | HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological Malignancies | April 1, 2023 | April 1, 2029 |
| NCT05554419 | Not yet recruiting | Phase 2 | Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia Following Initial Treatment, The ERASE Study (A MyeloMATCH Treatment Trial) | August 16, 2024 | January 31, 2025 |
| NCT06124157 | Not yet recruiting | Phase 3 | A Study Comparing the Combination of Dasatinib and Chemotherapy Treatment With or Without Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or Philadelphia Chromosome-Like (Ph-Like) ABL-Class B-Cell Acute Lymphoblastic Leukemia (B-ALL) | July 22, 2024 | December 1, 2030 |
| NCT06050941 | Not yet recruiting | Phase 2 | Reduced Intensive Idarubicin and Cytarabine Plus Venetoclax as First-line Treatment for Adults AML and MDS | April 2, 2024 | April 2, 2027 |
| NCT05907486 | Not yet recruiting | Phase 3 | The Use of N-acetylcysteine for Thrombotic Events After Allogenic Hematopoietic Stem Cell Transplantation | August 1, 2023 | December 1, 2025 |
| NCT05987696 | Not yet recruiting | Phase 1 | Natural Killer(NK) Cell Therapy in Acute Myeloid Leukemia | August 10, 2023 | August 31, 2026 |
| NCT05665075 | Recruiting | Phase 1 | Natural Killer (NK) Cell Therapy Targeting CD33 in Acute Myeloid Leukemia | December 24, 2022 | December 24, 2025 |
| NCT05645718 | Recruiting | Phase 2 | Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia | July 14, 2023 | December 31, 2029 |
| NCT03709758 | Recruiting | Phase 1 | Venetoclax in Combination With Intensive Induction and Consolidation Chemotherapy in Treatment Naïve AML | October 17, 2018 | June 1, 2025 |
| NCT04547049 | Recruiting | Phase 3 | A Study Comparing Haploidentical Hematopoietic Stem Cell Transplantations (HSCTs) From Young Non-first-degree and Older First-degree Donors in Hematological Malignancies | September 1, 2020 | December 31, 2025 |
| NCT03736616 | Recruiting | Phase 2 | Acalabrutinib Plus RICE for Relapsed/Refractory DLBCL | August 16, 2019 | September 2023 |
| NCT04530565 | Recruiting | Phase 3 | Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults | January 25, 2021 | July 1, 2028 |
| NCT03765541 | Recruiting | Phase 3 | Dexamethasone in Refractory or First Relapsed Acute Myeloid Leukemia | January 13, 2020 | December 2025 |
| NCT03793478 | Recruiting | Phase 1/Phase 2 | Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood | August 15, 2018 | May 1, 2027 |
| NCT03837873 | Recruiting | Phase 2 | DLCL002 Protocol for Patients With High Risk Aggressive B-cell Lymphoma | January 21, 2019 | September 1, 2024 |
| NCT00501826 | Recruiting | Phase 2 | Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma | July 11, 2007 | October 31, 2024 |
| NCT03897127 | Recruiting | Phase 3 | Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy With CPX-351 in Adult Patients With Newly Diagnosed AML and Intermediate- or Adverse Genetics | September 4, 2019 | March 2024 |
| NCT03913559 | Recruiting | Phase 2 | Inotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic Leukemia | May 14, 2019 | January 2025 |
| NCT03914625 | Recruiting | Phase 3 | A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia | July 3, 2019 | June 30, 2029 |
| NCT03926624 | Recruiting | Phase 3 | Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage | November 22, 2019 | December 2022 |
| NCT03959085 | Recruiting | Phase 3 | Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy | October 31, 2019 | March 31, 2030 |
| NCT04043494 | Recruiting | Phase 3 | International Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma | August 23, 2019 | November 22, 2027 |
| NCT01356290 | Recruiting | Phase 2 | Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma and ATRT | April 2014 | April 2026 |
| NCT04047641 | Recruiting | Phase 1/Phase 2 | Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | October 22, 2019 | December 31, 2025 |
| NCT04061239 | Recruiting | Phase 2 | Comparison of Therapies Before Stem Cell Transplantation in Patients With Higher Risk MDS and Oligoblastic AML | August 19, 2019 | September 2026 |
| NCT01371630 | Recruiting | Phase 1/Phase 2 | Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia | August 26, 2011 | December 25, 2025 |
| NCT06429098 | Recruiting | Phase 2 | Study of A Venetoclax-based, Anthracycline-free Regimen in Newly Diagnosed CBFβ::MYH11(+) AML | January 1, 2024 | December 31, 2027 |
| NCT05660473 | Recruiting | Phase 2 | Pediatric-inspired Regimen Combined With Venetoclax for Adolescent and Adult Patients With de Novo Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia | October 31, 2022 | December 30, 2027 |
| NCT04375631 | Recruiting | Phase 1 | CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia | December 3, 2020 | December 31, 2027 |
| NCT05665114 | Recruiting | Phase 1 | Natural Killer(NK) Cell Therapy in r/r AML | December 24, 2022 | December 24, 2025 |
| NCT04174612 | Recruiting | Phase 3 | AML Patients Bearing FLT3 Mutations Based on Peripheral Blast Clearance | April 24, 2020 | August 1, 2025 |
| NCT04195945 | Recruiting | Phase 2 | CPX-351 or CLAG-M Regimen for the Treatment of Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms in Medically Less-Fit Patients | March 11, 2020 | December 31, 2027 |
| NCT01515527 | Recruiting | Phase 2 | Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS) | February 7, 2012 | February 1, 2026 |
| NCT04214249 | Recruiting | Phase 2 | BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia | February 17, 2021 | July 31, 2024 |
| NCT04216524 | Recruiting | Phase 2 | Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm | May 29, 2020 | December 31, 2026 |
| NCT04275518 | Recruiting | Phase 1 | A Phase Ib Study of APG-115 Single Agent or in Combination With Azacitidine or Cytarabine in Patients With AML and MDS. | July 6, 2020 | December 31, 2025 |
| NCT04240002 | Recruiting | Phase 1/Phase 2 | A Study of Gilteritinib (ASP2215) Combined With Chemotherapy in Children, Adolescents and Young Adults With FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML) | September 4, 2020 | August 31, 2031 |
| NCT04250051 | Recruiting | Phase 1 | Ivosidenib and Combination Chemotherapy for the Treatment of IDH1 Mutant Relapsed or Refractory Acute Myeloid Leukemia | December 21, 2020 | December 1, 2028 |
| NCT05726110 | Recruiting | Phase 3 | Selinexor in Combination With HAD or CAG Rregimens in Relapsed or Refractory Acute Myeloid Leukemia | January 29, 2023 | December 31, 2024 |
| NCT05319587 | Recruiting | Phase 1/Phase 2 | Study of Liposomal Annamycin in Combination With Cytarabine for the Treatment of Subjects With Acute Myeloid Leukemia (AML) | September 29, 2022 | April 30, 2025 |
| NCT05735184 | Recruiting | Phase 1 | A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, or 7+3 in Patients With AML | July 18, 2023 | May 2027 |
| NCT02203526 | Recruiting | Phase 1 | Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma | August 14, 2014 | June 15, 2027 |
| NCT05761171 | Recruiting | Phase 2 | A Study of SNDX-5613 in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia | January 8, 2024 | December 31, 2027 |
| NCT02670707 | Recruiting | Phase 3 | Vinblastine/Prednisone Versus Single Therapy With Cytarabine for Langerhans Cell Histiocytosis (LCH) | March 7, 2016 | January 2029 |
| NCT05146739 | Recruiting | Phase 1 | Highest Dose of Uproleselan in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Mixed Phenotype Acute Leukemia Relapsed or Refractory and That Expresses E-selectin Ligand on the Cell Membrane | October 10, 2023 | December 31, 2024 |
| NCT02724163 | Recruiting | Phase 3 | International Randomised Phase III Clinical Trial in Children With Acute Myeloid Leukaemia | April 2016 | December 2032 |
| NCT05805098 | Recruiting | Phase 2/Phase 3 | Venetoclax Combined With Homoharringtonine and Cytarabine in Induction for AML | March 1, 2023 | March 1, 2028 |
| NCT05849662 | Recruiting | Phase 1/Phase 2 | A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia | May 10, 2024 | December 2029 |
| NCT05342584 | Recruiting | Phase 1 | Venetoclax Plus Intensive Chemotherapy in AML and Advanced MDS | May 25, 2022 | December 2028 |
| NCT05886049 | Recruiting | Phase 1 | Testing the Addition of an Anti-cancer Drug, SNDX-5613, to the Standard Chemotherapy Treatment (Daunorubicin and Cytarabine) for Newly Diagnosed Patients With Acute Myeloid Leukemia That Has Changes in NPM1 or MLL/KMT2A Gene | November 10, 2024 | December 31, 2027 |
| NCT05365035 | Recruiting | Phase 2 | A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes With Excess Blasts | September 23, 2022 | February 1, 2025 |
| NCT02813135 | Recruiting | Phase 1/Phase 2 | European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors | August 3, 2016 | August 2027 |
| NCT02835222 | Recruiting | Phase 2 | Selinexor With Combination With Induction/Consolidation Therapy in Acute Myeloid Leukemia Patients | February 2, 2018 | June 2025 |
| NCT05955261 | Recruiting | Phase 2 | A Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatric Patients With Acute Myeloid Leukemia | July 25, 2023 | March 2034 |
| NCT05183035 | Recruiting | Phase 3 | Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML) | October 1, 2022 | February 2032 |
| NCT05292664 | Recruiting | Phase 1 | Venetoclax Basket Trial for High Risk Hematologic Malignancies | March 29, 2023 | April 2, 2027 |
| NCT05959720 | Recruiting | Adult Acute Lymphoblastic Leukemia Treated With Pediatric Regimen in Brazil | September 5, 2023 | June 2030 | |
| NCT02877303 | Recruiting | Phase 2 | Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia | November 1, 2016 | November 1, 2026 |
| NCT05453903 | Recruiting | Phase 1 | A Study of JNJ-75276617 in Combination With Acute Myeloid Leukemia (AML) Directed Therapies | October 4, 2022 | March 5, 2026 |
| NCT05466318 | Recruiting | Phase 3 | ChiCGB vs BEAM in High-risk or R/R Lymphomas | July 1, 2022 | December 30, 2025 |
| NCT02926586 | Recruiting | Phase 4 | Fludarabine and Cytarabine Versus High-dose Cytarabine for CBF-AML | January 1, 2017 | July 2024 |
| NCT06001788 | Recruiting | Phase 1 | Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia | February 22, 2024 | August 2027 |
| NCT05476770 | Recruiting | Phase 1 | Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies | November 11, 2022 | November 11, 2027 |
| NCT06034470 | Recruiting | Phase 1 | Combination Chemotherapy (FLAG-Ida) With Pivekimab Sunirine (PVEK [IMGN632]) for the Treatment of Newly Diagnosed Adverse Risk Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms | December 18, 2023 | December 31, 2027 |
| NCT02981628 | Recruiting | Phase 2 | Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia | June 19, 2017 | March 31, 2026 |
| NCT05510089 | Recruiting | N/A | Etoposide+Cytarabine+PEG-rhG-CSF for Hematopoietic Stem Cell Mobilization in Patients With Hematological Malignancies | September 1, 2022 | December 31, 2024 |
| NCT03007147 | Recruiting | Phase 3 | Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia | August 8, 2017 | September 30, 2027 |
| NCT04898894 | Recruiting | Phase 1 | Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia | November 15, 2021 | July 2025 |
| NCT05536154 | Recruiting | N/A | Etoposide+Cytarabine+PEG-rhG-CSF as First Line Mobilization Regimen of Hematopoietic Stem Cells in Patients With Hematological Malignancies | November 1, 2022 | October 2024 |
| NCT06177067 | Recruiting | Phase 1 | Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia | April 19, 2024 | July 2026 |
| NCT04871607 | Recruiting | Phase 2 | Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma | November 2, 2021 | October 2, 2027 |
| NCT03206671 | Recruiting | Phase 3 | Treatment Protocol of the NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents | August 3, 2017 | August 2024 |
| NCT04801797 | Recruiting | Phase 2 | Venetoclax + Azacitidine vs. Induction Chemotherapy in AML | May 20, 2021 | January 1, 2026 |
| NCT03214562 | Recruiting | Phase 1/Phase 2 | Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia | September 26, 2017 | September 30, 2025 |
| NCT03250338 | Recruiting | Phase 3 | Study Investigating the Efficacy of Crenolanib With Chemotherapy vs Chemotherapy Alone in R/R FLT3 Mutated AML | June 5, 2018 | October 2024 |
| NCT03258931 | Recruiting | Phase 3 | Study of Crenolanib vs Midostaurin Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed FLT3 Mutated AML | August 15, 2018 | November 2024 |
| NCT03263572 | Recruiting | Phase 2 | Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia | November 29, 2017 | November 30, 2025 |
| NCT06221683 | Recruiting | Phase 2 | Clinical Study of Induction Therapy Options Based on Molecular Subtyping and MRD in Children and Adolescents With AML | March 2024 | December 2029 |
| NCT03286634 | Recruiting | Phase 2 | ASIA Down Syndrome Acute Lymphoblastic Leukemia 2016 | April 18, 2017 | March 31, 2033 |
| NCT06230224 | Recruiting | Phase 3 | A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma | February 15, 2024 | July 6, 2027 |
| NCT06262438 | Recruiting | Phase 2 | CHIP-AML22/Quizartinib: Quizartinib + Chemotherapy in Newly Diagnosed Pediatric FLT3-ITD+ and NPM1wt AML Patients | February 6, 2024 | June 2032 |
| NCT05554406 | Recruiting | Phase 2 | Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial) | February 10, 2025 | March 31, 2027 |
| NCT05564390 | Recruiting | Phase 2 | MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial) | February 10, 2025 | May 15, 2029 |
| NCT03412409 | Recruiting | Phase 2 | RIC Regimen for Elderly or High Comorbidity Burden Patients Receiving Haplo-HSCT | February 1, 2018 | September 1, 2025 |
| NCT06316960 | Recruiting | Phase 2 | Safety and Efficacy of Avapritinib in Relapsed or Refractory Pediatric CBF-AML With KIT Mutation | March 2024 | March 2027 |
| NCT03418038 | Recruiting | Phase 2 | Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia | March 23, 2018 | March 2026 |
| NCT06336395 | Recruiting | Phase 2 | Ma-Spore ALL 2020 Study | March 4, 2020 | March 2030 |
| NCT05157971 | Recruiting | Phase 1 | Venetoclax and a Pediatric-Inspired Regimen for the Treatment of Newly Diagnosed B Cell Acute Lymphoblastic Leukemia | March 17, 2022 | May 22, 2024 |
| NCT02115295 | Recruiting | Phase 2 | Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia | May 19, 2014 | May 31, 2026 |
| NCT06434662 | Recruiting | Phase 2 | Mitoxantrone Hydrochloride Liposome Injection, Cytarabine Combined With Venetoclax in the Treatment of R/R AML | February 29, 2024 | June 2026 |
| NCT04688021 | Recruiting | Phase 2 | A Single-arm Trial of Prophylactic Tocilizumab for Acute GVHD Prevention After Haploidentical HSCT. | December 3, 2020 | December 31, 2024 |
| NCT04687761 | Recruiting | Phase 1/Phase 2 | Clinical Trial to Assess the Safety and Tolerability of the Combination of Low-dose Cytarabine or Azacitidine Plus Venetoclax and Quizartinib in Newly Diagnosed AML Patients Aged Equal or More Than 60 Years Old | November 4, 2020 | November 2024 |
| NCT00801489 | Recruiting | Phase 2 | Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | April 4, 2007 | December 30, 2024 |
| NCT06361329 | Recruiting | Phase 3 | Comparing the Efficacy of VHAG and Traditional Chemotherapy Regimens in Newly Diagnosed ETP-ALL | April 2024 | March 31, 2027 |
| NCT05601466 | Recruiting | Phase 1 | Natural Killer(NK) Cell Therapy for Acute Myeloid Leukemia | October 28, 2022 | October 21, 2025 |
| NCT05303792 | Recruiting | Phase 2 | Testing the Combination of Inotuzumab Ozogamicin and Lower Dose Chemotherapy Compared to Usual Chemotherapy for Adults With B-Cell Acute Lymphoblastic Leukemia or B-Cell Lymphoblastic Lymphoma | February 27, 2023 | May 2028 |
| NCT05601830 | Recruiting | Phase 1 | Natural Killer(NK) Cell Therapy for AML Minimal Residual Disease | October 28, 2022 | October 21, 2025 |
| NCT05032183 | Recruiting | Phase 1/Phase 2 | Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma | February 17, 2022 | July 1, 2025 |
| NCT03570983 | Recruiting | Phase 2 | A Trial Comparing Single Agent Melphalan to Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) as a Preparative Regimen for Patients With Multiple Myeloma Undergoing High Dose Therapy Followed by Autologous Stem Cell Reinfusion | September 5, 2018 | December 2024 |
| NCT03571321 | Recruiting | Phase 1 | Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia | May 28, 2019 | September 5, 2027 |
| NCT04659616 | Recruiting | Phase 1 | Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia | January 14, 2021 | February 1, 2026 |
| NCT03585686 | Recruiting | Phase 2 | A Combination of Vemurafenib, Cytarabine and 2-chlorodeoxyadenosine in Children With LCH and BRAF V600E Mutation | June 26, 2018 | December 2023 |
| NCT03586609 | Recruiting | Phase 2 | Venetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine in Treating Patients With Previously Untreated Acute Myeloid Leukemia | October 25, 2018 | April 30, 2025 |
| NCT04626791 | Recruiting | Phase 2 | Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma | August 3, 2021 | August 3, 2028 |
| NCT03589729 | Recruiting | Phase 2 | Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers | September 19, 2018 | December 31, 2025 |
| NCT03591510 | Recruiting | Phase 2 | A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML | March 13, 2019 | February 15, 2029 |
| NCT05313958 | Recruiting | Phase 2/Phase 3 | Treateament of Newly Diagnosed Acute Monocytic Leukemia in Children | December 1, 2021 | March 30, 2026 |
| NCT05317403 | Recruiting | Phase 1 | Venetoclax to Augment Epigenetic Modification and Chemotherapy | March 31, 2023 | January 2027 |
| NCT03643276 | Recruiting | Phase 3 | Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017 | July 15, 2018 | July 14, 2028 |
| NCT03150693 | Suspended | Phase 3 | Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia | June 1, 2017 | August 2025 |
| NCT04546399 | Suspended | Phase 2 | A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL) | December 4, 2020 | June 30, 2028 |
| NCT03701308 | Suspended | Phase 2/Phase 3 | Daunorubicin and Cytarabine With or Without Uproleselan in Treating Older Adult Patients With Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy | March 28, 2019 | December 1, 2025 |
| NCT03900949 | Suspended | Phase 1 | Gentuzumab Ozogamicin and Midostaurin Combination With Standard Cytarabine and Danunorubi Midostaurin as a Novel Approach to Treating Patients With Newly Diagnosed FLT-3 Mutated Acute Myeloid Leukemia | March 13, 2019 | January 1, 2025 |
| NCT04797767 | Suspended | Phase 1 | Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms | February 4, 2022 | December 31, 2024 |
| NCT03983824 | Suspended | Phase 1 | Testing the Addition of an Anti-cancer Drug, M3814, to the Usual Treatment (Mitoxantrone, Etoposide, and Cytarabine) for Relapsed or Refractory Acute Myeloid Leukemia | May 5, 2020 | June 30, 2025 |
| NCT04778397 | Terminated | Phase 3 | Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been Treated | July 1, 2021 | March 25, 2024 |
| NCT03071276 | Terminated | Phase 2 | Selinexor in Combination With Fludarabine and Cytarabine in Patients With Refractory or Relapsed Acute Myeloid Leukemia | January 14, 2016 | April 30, 2019 |
| NCT00003729 | Terminated | Phase 2 | Combination Chemotherapy in Treating Children With Relapsed or Refractory Acute Lymphocytic Leukemia | December 1998 | |
| NCT00275106 | Terminated | Phase 3 | Prednisolone or Dexamethasone Combined With Chemotherapy in Treating Young Patients With Newly Diagnosed Lymphoblastic Lymphoma | September 2004 | August 2012 |
| NCT00882206 | Terminated | Phase 2 | Pre-reinductive Decitabine and Vorinostat in Relapsed Lymphoblastic Lymphoma or Acute Lymphoblastic Leukemia | April 2009 | January 2013 |
| NCT01350232 | Terminated | N/A | Treatment of Sickle Cell Anemia With Stem Cell Transplant | September 2009 | August 2011 |
| NCT02483000 | Terminated | Phase 1 | Anti-CD20 Radioimmunotherapy Before Chemotherapy and Stem Cell Transplant in Treating Patients With High-Risk B-Cell Malignancies | February 1, 2017 | September 2, 2020 |
| NCT03135028 | Terminated | Phase 1 | Entospletinib (ENTO) as Monotherapy and in Combination With Chemotherapy in Japanese Adults | May 19, 2017 | February 26, 2019 |
| NCT01801046 | Terminated | Phase 1 | Donor Stem Cell Transplant in Treating Patients With High Risk Acute Myeloid Leukemia | March 6, 2013 | August 20, 2017 |
| NCT00480987 | Terminated | Phase 1/Phase 2 | Oxaliplatin, Fludarabine, and Cytarabine in Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS) | July 2007 | August 2010 |
| NCT01701323 | Terminated | Phase 1 | Expanded Cord Blood Cell Infusion Following Combination Chemotherapy in Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia | December 10, 2012 | May 10, 2018 |
| NCT03735446 | Terminated | Phase 1 | Prexasertib in Combination With MEC in Relapsed/Refractory AML and High Risk MDS - a Phase I Trial | January 18, 2019 | March 29, 2019 |
| NCT01408160 | Terminated | Phase 1 | Immunotoxin Therapy and Cytarabine in Treating Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia | April 2013 | June 26, 2018 |
| NCT00096148 | Terminated | Phase 2 | Idarubicin and Cytarabine With or Without Bevacizumab in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | October 2004 | |
| NCT04113616 | Terminated | Phase 1/Phase 2 | An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 When Administered Alone and in Combination With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML) | September 25, 2019 | September 27, 2023 |
| NCT00219765 | Terminated | Phase 1/Phase 2 | Safety and Efficacy of Imatinib in Combination With High Dose Chemotherapy for Acute Phase Chronic Myelogenous Patients | May 2001 | January 2006 |
| NCT00439296 | Terminated | Phase 1/Phase 2 | ABT-751 With Chemotherapy for Relapsed Pediatric ALL | May 22, 2006 | September 23, 2009 |
| NCT01849276 | Terminated | Phase 1 | Metformin+Cytarabine for the Treatment of Relapsed/Refractory AML | March 11, 2015 | January 21, 2016 |
| NCT02545283 | Terminated | Phase 3 | A Study of Idasanutlin With Cytarabine Versus Cytarabine Plus Placebo in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) | December 30, 2015 | April 24, 2020 |
| NCT00907517 | Terminated | Phase 1 | Study of SCH 900776 (MK-8776) With and Without Cytarabine in Participants With Acute Leukemias (P05247) | July 29, 2009 | June 13, 2011 |
| NCT03634228 | Terminated | Phase 1/Phase 2 | Milademetan Tosylate and Low-Dose Cytarabine With or Without Venetoclax in Treating Participants With Recurrent or Refractory Acute Myeloid Leukemia | December 17, 2018 | April 3, 2022 |
| NCT05020665 | Terminated | Phase 3 | Entospletinib Plus Intensive Induction/Consolidation Chemotherapy in Newly Diagnosed NPM1-mutated AML | November 24, 2021 | March 30, 2023 |
| NCT05712278 | Terminated | Phase 1 | A Study to Investigate Use of Off-the-shelf Natural Killer (NK) Cells (SAR445419) in Relapsed/Refractory Acute Myeloid Leukemia | June 16, 2023 | March 12, 2024 |
| NCT04326439 | Terminated | Phase 2 | AflacLL1901 (CHOA-AML) | January 24, 2020 | March 15, 2022 |
| NCT03488225 | Terminated | Phase 2 | Combination Chemotherapy and Inotuzumab Ozogamicin in Treating Patients With B Acute Lymphoblastic Leukemia | March 28, 2018 | April 2, 2020 |
| NCT04196010 | Terminated | Phase 1 | Continuous Infusion Chemotherapy (CI-CLAM) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms | May 8, 2020 | October 13, 2021 |
| NCT01500161 | Terminated | Phase 2 | Pooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing Allogeneic Stem Cell Transplant Without Related HLA-Match | November 2011 | November 2013 |
| NCT01653418 | Terminated | Phase 2 | Phase II Study of V-BEAM Conditioning Regimen Prior to Second Autologous Stem Cell Transplantation | September 2012 | December 2013 |
| NCT00863434 | Terminated | Phase 2 | Clofarabine and Cytarabine in Treating Patients With Acute Myeloid Leukemia With Minimal Residual Disease | February 2009 | |
| NCT01005914 | Terminated | Phase 2 | Pegaspargase and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia | June 2009 | May 2014 |
| NCT00354107 | Terminated | Phase 1/Phase 2 | Ifosfamide, Carboplatin, Etoposide, and SGN-30 in Treating Young Patients With Recurrent Anaplastic Large Cell Lymphoma | January 2007 | January 2010 |
| NCT03259516 | Terminated | Phase 1/Phase 2 | Nivolumab With Chemotherapy in Refractory MDS | May 25, 2017 | December 25, 2018 |
| NCT02433483 | Terminated | Phase 2 | Microtransplantation to Treat Refractory or Relapsed Hematologic Malignancies in Younger Patients | May 22, 2015 | May 8, 2017 |
| NCT01607645 | Terminated | Phase 2 | Decitabine Followed by Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory AML and MDS | July 2012 | September 2013 |
| NCT02440568 | Terminated | Phase 1/Phase 2 | AML-02: Omacetaxine With Standard-of-Care Induction With Cytarabine & Idarubicin in Newly-Diagnosed AML Patients | June 5, 2015 | November 30, 2018 |
| NCT01621477 | Terminated | Phase 2 | T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant | August 2012 | December 2015 |
| NCT03518112 | Terminated | Phase 2 | Low-Intensity Chemotherapy and Blinatumomab in Treating Patients With Philadelphia Chromosome Negative Relapsed or Refractory Acute Lymphoblastic Leukemia | April 18, 2018 | May 27, 2021 |
| NCT00074165 | Terminated | Phase 2 | Treating Patients With Recurrent PCNSL With Carboplatin/BBBD and Adding Rituxan To The Treatment Regimen | January 2003 | December 2010 |
| NCT01636609 | Terminated | Phase 1 | Tosedostat and Cytarabine or Azacitidine in Treating Older Participants With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome | November 20, 2012 | July 4, 2019 |
| NCT02635074 | Terminated | Phase 1 | Ibrutinib, Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | November 2016 | November 10, 2017 |
| NCT00517699 | Terminated | Phase 2 | A Study of MabThera (Rituximab) in Primary Central Nervous System Lymphoma. | September 2007 | March 2009 |
| NCT03724084 | Terminated | Phase 1/Phase 2 | Pinometostat With Standard Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and MLL Gene Rearrangement | April 10, 2019 | November 14, 2022 |
| NCT02532010 | Terminated | Phase 2 | Pacritinib Combined With Decitabine or Cytarabine in Older Patients With AML | June 15, 2015 | October 24, 2017 |
| NCT02198482 | Terminated | Phase 2 | Trial of Intensive Chemotherapy With or Without Volasertib in Patients With Newly Diagnosed High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) | February 2016 | November 2016 |
| NCT00335140 | Terminated | Phase 2 | Rituximab and Combination Chemotherapy in Treating Patients With Primary Central Nervous System Lymphoma | August 23, 2007 | July 2015 |
| NCT02049801 | Terminated | Phase 1 | MEK Inhibitor MEK162, Idarubicin, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | December 2014 | November 1, 2017 |
| NCT02343939 | Terminated | Phase 1/Phase 2 | Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML) | July 1, 2015 | February 21, 2019 |
| NCT02676323 | Terminated | Phase 1 | Panobinostat With Fludarabine and Cytarabine for Treatment of Children With Acute Myeloid Leukemia or Myelodysplastic Syndrome | May 3, 2016 | April 9, 2018 |
| NCT01904643 | Terminated | Phase 1 | Lenalidomide and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | February 2014 | July 18, 2015 |
| NCT00058461 | Terminated | Phase 2 | Combination Chemotherapy and Rituximab in Treating Young Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia | November 2003 | |
| NCT02029417 | Terminated | Phase 2 | Omacetaxine Mepesuccinate, Cytarabine, and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia | July 2014 | December 2015 |
| NCT01960387 | Terminated | Phase 2 | Phase II Clofarabine and Cytarabine for Newly Diagnosed Acute Myeloid Leukemia | October 2013 | March 2015 |
| NCT00505921 | Terminated | Phase 2 | Autologous and Allogenic Transplantation With Campath-1H for T-Cell Lymphoma | March 2003 | November 2009 |
| NCT02366663 | Terminated | Phase 3 | BEAM vs. 90-Yttrium Ibritumomab Tiuxetan (Zevalin®)/BEAM With ASCT for Relapsed DLBCL | January 2015 | October 2016 |
| NCT03860844 | Terminated | Phase 2 | Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia | August 6, 2019 | May 26, 2023 |
| NCT00583102 | Terminated | Phase 1/Phase 2 | Dose Escalation Phase I/II Study of Lovastatin With High-Dose Cytarabine for Refractory or Relapsed AML | June 2001 | June 2013 |
| NCT03519984 | Terminated | Phase 1 | EphB4-HSA Fusion Protein and Cytarabine /or Liposomal Vincristine in Patients With Recurrent or Refractory Acute Leukemia | May 9, 2018 | November 24, 2020 |
| NCT01193400 | Terminated | Phase 2 | Clofarabine and Low-dose Cytarabine Followed by Consolidation Therapy in AML Patients Age Greater Than or Equal to 60 Years | September 2010 | February 2012 |
| NCT02229266 | Terminated | Phase 2 | Randomised Controlled Phase-2 Trial to Determine the Efficacy of Adoptive Immunotherapy With NK Cells in High-risk AML | September 2015 | April 22, 2017 |
| NCT00593645 | Terminated | Phase 2 | Clofarabine, Cytarabine, and Thymoglobulin for Allogeneic Transplantation | November 2007 | July 2009 |
| NCT02105116 | Terminated | N/A | AML Therapy With Irradiated Allogeneic Cells | February 2014 | December 16, 2015 |
| NCT01880437 | Terminated | Phase 2 | A Study of Vismodegib in Patients With Relapsed/Refractory Acute Myelogenous Leukemia and Relapsed Refractory High-Risk Myelodysplastic Syndrome | September 2013 | November 2014 |
| NCT00609739 | Terminated | Phase 1/Phase 2 | Cytosine Arabinoside and Mitoxantrone for Patients With Juvenile Myelomonocytic Leukemia Receiving Repeat Stem Cell Transplantation | June 1999 | June 2010 |
| NCT02255162 | Terminated | Phase 1 | Lenalidomide in Combination With Microtransplantation as Post-remission Therapy in AML | January 2015 | December 2016 |
| NCT00503880 | Terminated | Phase 1/Phase 2 | Clofarabine, Cytarabine, and G-CSF in Treating Patients With Myelodysplastic Syndromes | May 7, 2007 | October 13, 2009 |
| NCT03381118 | Terminated | Phase 2 | Haploidentical Lymphocytes With Nivolumab/Ara-C as Consolidation in Elderly AML Patients | June 30, 2017 | September 30, 2018 |
| NCT00126191 | Terminated | Phase 2 | Intensive Chemotherapy and Rituximab in the Treatment of Burkitt Lymphoma | July 2005 | June 2011 |
| NCT01034410 | Terminated | Phase 2 | A Study of AS1411 Combined With Cytarabine in the Treatment of Patients With Primary Refractory or Relapsed Acute Myeloid Leukemia | January 2010 | January 2011 |
| NCT00632827 | Terminated | Phase 2 | Treatment of PTCL With Aggressive Induction Therapy Followed by Autologous SCT Using Denileukin Diftitox (Ontak) | July 1, 2008 | June 23, 2016 |
| NCT02412475 | Terminated | Phase 1 | Epigenetic Reprogramming in Relapse AML | February 21, 2015 | June 21, 2017 |
| NCT02875093 | Terminated | Phase 1 | Ph 1 Study of ADI-PEG 20 Plus Low Dose Cytarabine in Older Patients With AML | January 20, 2017 | July 10, 2019 |
| NCT02109627 | Terminated | Phase 1 | Ficlatuzumab With High Dose Cytarabine in Relapsed and Refractory AML | May 1, 2015 | December 2, 2019 |
| NCT00920153 | Terminated | Phase 3 | Three Different Therapy Regimens in Treating Patients With Previously Untreated Hodgkin Lymphoma | May 2008 | March 2016 |
| NCT00023920 | Terminated | Phase 2 | Bevacizumab, Idarubicin, and Cytarabine in Treating Patients With Blast Phase Chronic Myelogenous Leukemia | July 2001 | |
| NCT02520011 | Terminated | Phase 2 | Alvocidib Biomarker-driven Phase 2 AML Study | March 14, 2016 | February 12, 2020 |
| NCT01876953 | Terminated | Phase 1/Phase 2 | Dasatinib, Cytarabine, and Idarubicin in Treating Patients With High-Risk Acute Myeloid Leukemia | September 13, 2013 | April 25, 2018 |
| NCT01187810 | Terminated | Phase 1 | Fenretinide in Children With Recurrent/Resistant ALL, AML, and NHL | August 2010 | April 2018 |
| NCT02419469 | Terminated | Phase 2 | Augmented Berlin-Frankfurt-Munster Therapy Plus Ofatumumab for Young Adults With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma | November 13, 2015 | June 22, 2017 |
| NCT02419755 | Terminated | Phase 2 | Bortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies | April 14, 2015 | December 31, 2016 |
| NCT00928200 | Terminated | Phase 1 | Erwinase for Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) (IND 104224) | April 13, 2009 | June 4, 2010 |
| NCT02954653 | Terminated | Phase 1 | A Study Of PF-06747143, As Single Agent Or In Combination With Standard Chemotherapy In Adult Patients With Acute Myeloid Leukemia | November 28, 2016 | December 5, 2017 |
| NCT02957032 | Terminated | Phase 1 | A Study of the Tumor-targeting Human F16IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Very Low-dose Cytarabine in Patients With AML Relapse After Allogeneic Hematopoietic Stem Cell Transplantation | April 13, 2016 | September 29, 2023 |
| NCT00939653 | Terminated | Phase 2 | T2007-002 Clofarabine, Etoposide, Cyclophosphamide in Relapsed Acute Myelogenous Leukemia (AML) | July 10, 2009 | July 15, 2011 |
| NCT02983097 | Terminated | Phase 1/Phase 2 | Therapy of Non-Hodgkin-Lymphoma by Combination of Lenalidomide + Rituximab, Dexa, High-dose ARA-C and CisP | November 2010 | April 28, 2015 |
| NCT02420717 | Terminated | Phase 2 | Ruxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia | July 15, 2015 | January 20, 2021 |
| NCT01186328 | Terminated | Phase 1 | EZN-3042 Administered With Re-induction Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL) | August 24, 2010 | January 10, 2012 |
| NCT01027923 | Terminated | Phase 1 | IV Plerixafor With Mitoxantrone Etoposide and Cytarabine for Acute Myeloid Leukemia (AML) | May 2010 | September 2011 |
| NCT00281879 | Terminated | Phase 2 | Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer | February 2006 | March 2008 |
| NCT03850535 | Terminated | Phase 1/Phase 2 | A Study Evaluating the Safety and Efficacy of Idasanutlin in Combination With Cytarabine and Daunorubicin in Patients Newly Diagnosed With Acute Myeloid Leukemia (AML) and the Safety and Efficacy of Idasanutlin in the Maintenance of First AML Complete Remission | March 25, 2019 | September 10, 2020 |
| NCT00022490 | Terminated | Phase 2 | Imatinib Mesylate Plus Cytarabine in Treating Patients With Chronic Myelogenous Leukemia | June 2001 | July 2011 |
| NCT02305563 | Terminated | Phase 1/Phase 2 | An Investigational Immuno-therapy Study of Ulocuplumab in Combination With Low Dose Cytarabine in Patients With Newly Diagnosed Acute Myeloid Leukemia | January 27, 2015 | June 4, 2019 |
| NCT00124644 | Terminated | Phase 1 | Combination Chemotherapy and Tipifarnib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | March 2006 | January 2008 |
| NCT00002499 | Unknown status | Phase 2/Phase 3 | Combination Chemotherapy in Treating Children With Relapsed Acute Lymphocytic Leukemia | January 1990 | |
| NCT00002481 | Unknown status | Phase 2 | Combination Chemotherapy and Radiation Therapy Plus Bone Marrow Transplantation in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma | March 1990 | |
| NCT00317408 | Unknown status | N/A | Combination Chemotherapy Followed By Stem Cell Transplant in Treating Young Patients With Progressive or Relapsed Anaplastic Large Cell Lymphoma | April 2004 | |
| NCT02275663 | Unknown status | Phase 2 | Azacytidine Plus FLAG for Relapsed or Refractory AML | December 2014 | October 2018 |
| NCT05404516 | Unknown status | Phase 2 | Combination of Sorafenib With Standard Therapy in Newly Diagnosed Adult CBF AML | January 1, 2020 | December 31, 2023 |
| NCT00209833 | Unknown status | Phase 2/Phase 3 | Treatment of Adults Aged Up to 60 Years With De Novo Acute Myeloblastic Leukaemia,Secondary AML, or RAEB-T | January 1999 | September 2005 |
| NCT00199147 | Unknown status | Phase 4 | Efficacy of G-CSF-Priming in Elderly AML Patients | January 2000 | |
| NCT00180128 | Unknown status | Phase 4 | AIDA2000 - Risk-Adapted Therapy for Patients With Acute Promyelocytic Leukemia | January 2000 | November 2012 |
| NCT02413021 | Unknown status | Phase 1 | The Effect of Deferasirox on Response Rate of Acute Leukemia Patients Not Treated by Standard Chemotherapy Regimens | May 2016 | October 2016 |
| NCT00131053 | Unknown status | Phase 2 | Applying Pediatric Regimens to Younger Adult Patients With Acute Lymphoblastic Leukemia (ALL) | September 2002 | September 2011 |
| NCT02432872 | Unknown status | N/A | Treatment of Older Adult Acute Myeloid Leukemia Patients Aged 55 to 65 Years | April 2015 | May 2021 |
| NCT00131027 | Unknown status | Phase 3 | High-Dose Methotrexate (MTX) for Adult Acute Lymphoblastic Leukemia (ALL) | September 2002 | September 2011 |
| NCT02488408 | Unknown status | Phase 1/Phase 2 | A Phase Ib/II Multicenter Open-label Study of Bemcentinib (BGB324) in Patients With AML or MDS | September 2014 | April 2022 |
| NCT02502968 | Unknown status | Phase 2 | BL-8040 Addition to Consolidation Therapy in AML Patients | September 2015 | |
| NCT02638428 | Unknown status | Phase 2 | Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy | December 2015 | December 2023 |
| NCT00069966 | Unknown status | Phase 2 | Pixantrone, Cytarabine, Methylprednisolone, and Cisplatin in Treating Patients With Aggressive Non-Hodgkin's Lymphoma in First Relapse | April 2003 | |
| NCT02660762 | Unknown status | Phase 2 | Modified MRCUKALLⅫ/ECOGE2993 Regimen for ALL | January 2016 | January 2019 |
| NCT02717884 | Unknown status | Phase 1/Phase 2 | Study of Sensitization of Non-M3 AML Blasts to ATRA by Epigenetic Treatment With Tranylcypromine (TCP) | May 2015 | December 2021 |
| NCT00053105 | Unknown status | Phase 1 | Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma | February 2002 | |
| NCT00047268 | Unknown status | Phase 3 | Donor Stem Cell Transplant With or Without Chemotherapy in Treating Children With Primary Myelodysplastic Syndrome | July 1998 | |
| NCT02758925 | Unknown status | Phase 2 | CyBeR Association in Relapsed/Refractory DLBCL | June 2016 | December 2018 |
| NCT00028847 | Unknown status | Phase 1/Phase 2 | Imatinib Mesylate and Cytarabine in Treating Patients With Newly Diagnosed Chronic Myeloid Leukemia | April 2001 | |
| NCT00025636 | Unknown status | Phase 3 | Combination Chemotherapy and Peripheral Stem Cell Transplant in Treating Patients With Relapsed Hodgkin's Lymphoma | July 2001 | |
| NCT02848183 | Unknown status | Phase 2 | Optimal Treatment Strategy Based on for Pediatric AML | January 2016 | |
| NCT02858804 | Unknown status | Phase 4 | EDOCH Alternating With DHAP for New Diagnosed Younger MCL | January 2016 | June 2020 |
| NCT00025402 | Unknown status | Phase 3 | Chemotherapy and Biological Therapy With or Without Bone Marrow or Peripheral Stem Cell Transplant in Treating Patients With Chronic Myelogenous Leukemia | July 1997 | |
| NCT02894645 | Unknown status | Phase 4 | Malaysia-Singapore Acute Lymphoblastic Leukemia 2010 Study | October 2008 | |
| NCT02937662 | Unknown status | Phase 2 | Efficacy of Idarubicin, Cytarabine and Cyclophosphamide (IAC) Regimen in Relapsed/Refractory AML | October 2016 | December 2019 |
| NCT02985372 | Unknown status | Phase 3 | Decitabine in Combination With Low-dose Cytarabine in Elderly Patients With Acute Myeloid Leukemia | December 2016 | December 2019 |
| NCT03016988 | Unknown status | Phase 2 | The Efficacy and Safety of Bortezomib Combined With Fludarabine and Cytarabine Treatment for Mantle Cell Lymphoma | January 2017 | December 2020 |
| NCT03031249 | Unknown status | Phase 1/Phase 2 | Efficacy and Safety of ATO Plus ATRA in Nucleophosmin-1 Mutated Acute Myeloid Leukemia | February 8, 2017 | December 2022 |
| NCT03031262 | Unknown status | Phase 1/Phase 2 | Efficacy and Safety of Chidamide in CBF Leukemia | February 8, 2017 | December 2022 |
| NCT00016887 | Unknown status | Phase 3 | Chemotherapy Followed by Radiation Therapy and Peripheral Stem Cell Transplant Compared With Chemotherapy Plus Interferon Alfa in Treating Patients With Stage III or Stage IV Mantle Cell Lymphoma | December 2000 | |
| NCT00006045 | Unknown status | Phase 3 | Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Refractory or Relapsed Acute Myelogenous Leukemia | March 2000 | |
| NCT00004903 | Unknown status | Phase 2 | Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma | October 1999 | |
| NCT03181815 | Unknown status | Phase 2 | Cladribine in Combination With CAG in Patients With Refractory/Relapsed Acute Myeloid Leukemia | January 1, 2016 | December 31, 2019 |
| NCT03318419 | Unknown status | Phase 2 | Cladribine in Combination With GAP in Patients With Refractory/Relapsed Acute Lymphoblastic Leukemia | January 1, 2016 | December 31, 2020 |
| NCT00550992 | Unknown status | N/A | Different Therapies in Treating Infants With Newly Diagnosed Acute Leukemia | January 2006 | |
| NCT00558519 | Unknown status | Phase 2 | Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia | March 12, 2008 | |
| NCT00004128 | Unknown status | Phase 3 | Combination Chemotherapy, Interleukin-2, and Peripheral Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia | September 1999 | |
| NCT03356080 | Unknown status | Phase 2 | DLAAG in the Treatment of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome With Blast Excess | July 7, 2017 | July 7, 2020 |
| NCT03381781 | Unknown status | Phase 2 | Decitabine,Cytarabine and Arsenic Trioxide for Acute Myeloid Leukemia With p53 Mutations | March 2018 | November 2020 |
| NCT03384212 | Unknown status | Phase 3 | CBA Versus FBA Conditioning Followed by Allogeneic HSCT in Treatment of High Risk and Refractory AML | August 1, 2016 | July 31, 2022 |
| NCT03384225 | Unknown status | Phase 3 | CBA Versus FBA Conditioning Followed by Haploidentical Allogeneic HSCT in Treatment of High Risk and Refractory AML | August 1, 2016 | July 31, 2022 |
| NCT00647049 | Unknown status | Phase 2 | Freiburg ZNS-NHL Study | January 2007 | August 2013 |
| NCT00651261 | Unknown status | Phase 3 | Daunorubicin, Cytarabine, and Midostaurin in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | April 2008 | |
| NCT03412266 | Unknown status | Phase 2 | RIC Regimen for Low- and Intermediate-risk MDS Receiving Haplo-HSCT | February 1, 2018 | March 1, 2023 |
| NCT00669812 | Unknown status | Phase 2 | High-Dose Chemotherapy Given Together With Peripheral Blood Stem Cell Transplant in Treating Patients With Intestinal T-Cell Lymphoma | February 2008 | |
| NCT00689845 | Unknown status | N/A | Combination Chemotherapy and Rituximab in Treating Patients With Primary Mediastinal Diffuse Large B-Cell Lymphoma | June 2007 | |
| NCT00544999 | Unknown status | Phase 1 | Everolimus, Cytarabine, and Daunorubicin in Treating Patients With Relapsed Acute Myeloid Leukemia | September 2007 | |
| NCT00720447 | Unknown status | Phase 2 | Donor Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma | November 2008 | |
| NCT00764907 | Unknown status | Phase 3 | Risk-Adjusted Combination Chemotherapy in Treating Young Patients With Acute Lymphoblastic Leukemia | November 2002 | |
| NCT03507842 | Unknown status | Phase 3 | A Prospective Randomized Comparison of HDAC vs AD in the Induction Chemothrapy for AML. | March 1, 2018 | December 31, 2020 |
| NCT03553238 | Unknown status | Phase 2/Phase 3 | Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult ETP-ALL | February 14, 2016 | August 30, 2020 |
| NCT00838240 | Unknown status | Phase 1/Phase 2 | Clofarabine, Cytarabine, and Idarubicin in Treating Patients With Intermediate-Risk or High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplasia | November 2008 | |
| NCT03564704 | Unknown status | Phase 2/Phase 3 | Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult T-LBL/ALL | February 14, 2016 | May 30, 2021 |
| NCT00004086 | Unknown status | Phase 1 | Radiolabeled Monoclonal Antibody, Combination Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory B-Cell Cancer | June 1997 | |
| NCT03583424 | Unknown status | Phase 1/Phase 2 | Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma | September 10, 2018 | December 31, 2022 |
| NCT00003827 | Unknown status | Phase 2 | Combination Chemotherapy in Treating Patients With Myelodysplastic Syndrome | January 1999 | |
| NCT00908180 | Unknown status | Phase 2 | Carmustine, Etoposide, Cytarabine, Melphalan, and Alemtuzumab Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma | July 2009 | |
| NCT00003815 | Unknown status | Phase 3 | Chemotherapy and Radiation Therapy Plus Bone Marrow Transplantation in Treating Patients With Aggressive Non-Hodgkin's Lymphoma | June 1994 | |
| NCT00974792 | Unknown status | Phase 2 | Combination Chemotherapy and Rituximab in Treating Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma | January 2006 | |
| NCT01005758 | Unknown status | Phase 2 | Combination Chemotherapy in Treating Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia | January 2009 | |
| NCT00003758 | Unknown status | Phase 2 | Combination Chemotherapy in Treating Patients With Relapsed Acute Myelogenous Leukemia | December 1998 | |
| NCT00003728 | Unknown status | Phase 3 | Combination Chemotherapy Plus Steroid Therapy in Treating Children With Acute Lymphoblastic Leukemia or Lymphoblastic Non-Hodgkin's Lymphoma | December 1998 | |
| NCT00003602 | Unknown status | Phase 3 | Combination Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia | March 1998 | |
| NCT00003578 | Unknown status | Phase 3 | High Dose Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Intermediate- or High-Grade Non-Hodgkin's Lymphoma | January 1993 | |
| NCT00003437 | Unknown status | Phase 3 | Hormone Therapy Plus Chemotherapy in Treating Children With Acute Lymphoblastic Leukemia | January 1997 | |
| NCT04024241 | Unknown status | Medium Dose of Cytarabine and Mitoxantrone | September 1, 2017 | August 31, 2019 | |
| NCT00003423 | Unknown status | Phase 3 | Combination Chemotherapy in Treating Children With Non-Hodgkin's Lymphoma | May 1995 | |
| NCT04112589 | Unknown status | Phase 1/Phase 2 | A Clinical Trial to Assess the Efficacy and Safety of the Combination of a Drug Call Quizartinib With Chemotherapy (FLAG-IDA) in Patients With Acute Myeloid Leukemia That Has Not Responded to the First Treatment or That Has Returned After the First Treatment | December 26, 2019 | December 2023 |
| NCT01414231 | Unknown status | Phase 3 | Comparison of the OSHO Protocol to a Standard Arm Protocol of the German AML Intergroup in Patients With AML<60a | April 2002 | July 2014 |
| NCT04121819 | Unknown status | Phase 2 | AraC for Newly Diagnosed Adult Langerhans Cell Histiocytosis | October 1, 2019 | December 31, 2021 |
| NCT00002926 | Unknown status | Phase 3 | Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia | December 1996 | |
| NCT00002869 | Unknown status | Phase 3 | Interferon Alfa in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia | April 1995 | |
| NCT00002771 | Unknown status | Phase 3 | Chemotherapy, Interferon, and Bone Marrow Transplantation in Treating Patients With Chronic Myelogenous Leukemia | January 1995 | |
| NCT01627041 | Unknown status | Phase 2 | Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia | September 16, 2011 | |
| NCT04254640 | Unknown status | Phase 2 | Efficacy and Safety of Cladribine in Combination With CAG in Newly Diagnosed Unfit Patients With AML | March 1, 2021 | December 31, 2023 |
| NCT00002701 | Unknown status | Phase 3 | Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Acute Promyelocytic Leukemia | October 1995 | |
| NCT00360750 | Unknown status | N/A | Chemotherapy With or Without Radiation Therapy or Observation in Treating Young Patients With Advanced Retinoblastoma Who Have Undergone Surgery to Remove the Eye | September 2005 | |
| NCT00002658 | Unknown status | Phase 3 | Combination Chemotherapy, Biological Therapy, and Bone Marrow Transplantation in Treating Patients With Acute Myeloid Leukemia | January 1994 | |
| NCT00002549 | Unknown status | Phase 3 | Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Acute Myelogenous Leukemia | November 1993 | |
| NCT00002532 | Unknown status | Phase 2 | Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphocytic Leukemia | January 1993 | |
| NCT00354276 | Unknown status | Phase 2 | VNP40101M Followed by Cytarabine in Treating Older Patients With Acute Myeloid Leukemia | May 2006 | |
| NCT00002531 | Unknown status | Phase 2 | Combination Chemotherapy in Treating Adults With Acute Lymphocytic Leukemia | January 1993 | |
| NCT05049473 | Unknown status | Phase 2 | Treatment of Mature B-ALL and Burkitt Lymphoma (BL) in Adult Patients. BURKIMAB-14. | January 2014 | January 2024 |
| NCT05053425 | Unknown status | N/A | Bcl-2 Inhibitors Combined With Azacytidine and Chemotherapy in Elderly Patients With Previously Untreated AML | October 20, 2021 | March 18, 2023 |
| NCT00343369 | Unknown status | N/A | Combination Chemotherapy in Treating Young Patients With Acute Lymphoblastic Leukemia | January 2003 | |
| NCT02024308 | Unknown status | Phase 4 | AML1-ETO Acute Myeloid Leukemia With Fludarabine and Cytarabine Chemotherapy | November 2010 | December 2016 |
| NCT01067274 | Withdrawn | Phase 3 | ALFA-0703 Study in Older Patients With Acute Myeloblastic Leukemia (AML) | April 2010 | |
| NCT03719560 | Withdrawn | Phase 2 | Early Systemic Central Nervous System Prophylaxis in Diffuse Large B-cell Lymphoma | July 1, 2019 | December 31, 2025 |
| NCT00513188 | Withdrawn | N/A | Combination Chemotherapy and Denileukin Diftitox in Treating Patients With Newly Diagnosed T-Cell Non-Hodgkin Lymphoma | February 2007 | |
| NCT01769911 | Withdrawn | N/A | Genetically Modified Peripheral Blood Stem Cell Transplant in Treating Patients With HIV-Associated Non-Hodgkin or Hodgkin Lymphoma | February 2015 | |
| NCT03579927 | Withdrawn | Phase 1/Phase 2 | CAR.CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood NK Cells, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Participants With B-cell Lymphoma | October 3, 2019 | October 3, 2019 |
| NCT03491579 | Withdrawn | Phase 1 | Epacadostat, Cladribine and Cytarabine (ECC) in AML | December 2018 | October 2019 |
| NCT00734773 | Withdrawn | Early Phase 1 | Pilot Study of MGd + High-dose MTX-Based Chemoimmunotherapy + RT for Newly Dx PCNSL | November 2008 | |
| NCT00723658 | Withdrawn | Phase 2 | S0629, Observation or Combination Chemotherapy, Bortezomib, Thalidomide, and Rituximab Followed By Two Autologous Peripheral Blood Stem Cell Transplants in Treating Patients With Waldenstrom Macroglobulinemia | September 2008 | |
| NCT00004114 | Withdrawn | Phase 1 | Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Hematologic Cancer | ||
| NCT03444649 | Withdrawn | Phase 1 | Epacadostat, Idarubicin and Cytarabine (EIC) in AML | September 2018 | October 2019 |
| NCT03324243 | Withdrawn | Phase 2 | A Study of Crenolanib With Fludarabine and Cytarabine in Pediatric Patients With Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia | January 2018 | December 2020 |
| NCT00004878 | Withdrawn | Phase 2 | Donor Lymphocytes to Prevent Graft-Versus-Host Disease in Patients With Chronic Myeloid Leukemia | ||
| NCT03207334 | Withdrawn | Phase 2 | iCare4: Genomic Signatures With Midostaurin in Acute Myeloid Leukemia (UF-HEM-004) | November 2018 | January 2022 |
| NCT05228249 | Withdrawn | Phase 1 | Loncastuximab Tesirine in Combination With Chemotherapy Prior to Stem Cell Transplant for the Treatment of Recurrent or Refractory Diffuse Large B-Cell Lymphoma | April 2023 | October 1, 2027 |
| NCT05320380 | Withdrawn | Phase 1/Phase 2 | A Study of the Drug IMGN632 in Children With Leukemia That Has Come Back After Treatment or is Difficult to Treat | August 1, 2023 | September 1, 2023 |
| NCT00310128 | Withdrawn | Phase 2 | Combination Chemotherapy Followed by Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin's Lymphoma | February 2006 | |
| NCT01843179 | Withdrawn | Phase 2 | Sulindac for Patients With AML | January 2014 | January 2014 |
| NCT06210750 | Withdrawn | Phase 2 | Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL) | August 9, 2024 | September 22, 2026 |
| NCT00005998 | Withdrawn | Phase 2 | Peripheral Stem Cell Transplantation With Specially Treated Stem Cells in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Disease | January 2000 | March 2003 |
| NCT00019409 | Withdrawn | Phase 3 | Radiation Therapy to the Head or Intrathecal Chemotherapy Plus High Dose Cytarabine in Preventing CNS Disease in Children With Acute Lymphoblastic Leukemia | October 1999 | July 2001 |
| NCT02905994 | Withdrawn | Phase 1 | Volasertib Combined With Induction Chemotherapy in Acute Myeloid Leukemia | September 2016 | February 2017 |
| NCT02791919 | Withdrawn | Phase 1 | Wee1 Kinase Inhibitor AZD1775 and Combination Chemotherapy in Treating Children, Adolescents and Young Adults With Relapsed or Refractory Acute Myeloid Leukemia | May 25, 2017 | May 31, 2019 |
| NCT05330377 | Withdrawn | Phase 1 | GM-CLAG in Relapsed/Refractory FLT3-mutated AML | March 2023 | May 30, 2032 |
| NCT02718755 | Withdrawn | Phase 2 | Phase II Study of Fludarabine, Cytarabine (ARA-C) and Erwinase IV in Patients With Relapsed or Refractory Hematologic Malignancies | May 2018 | May 2022 |
| NCT02680951 | Withdrawn | Phase 1 | Dasatinib in Combination With Chemotherapy for Relapsed or Refractory Core Binding Factor Acute Myeloid Leukemia | December 2015 | December 15, 2017 |
| NCT02587871 | Withdrawn | Phase 2 | Donor Cellular Therapy After Cytarabine in Treating Patients With Intermediate-Risk Acute Myeloid Leukemia in Remission | December 12, 2018 | November 12, 2022 |
| NCT00002761 | Withdrawn | Phase 1/Phase 2 | Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous Leukemia | February 1996 | October 2007 |
| NCT00411281 | Withdrawn | Phase 3 | Low-Dose Cytarabine in Treating Infants With Down Syndrome and Transient Myeloproliferative Disorder | March 2006 | November 2007 |
| NCT02532192 | Withdrawn | Phase 1 | A Phase Ib Study of Belinostat With RDHAP Chemotherapy (Dexamethasone, Cytarabine, Cisplatinum) in Adults With Relapsed or Refractory Diffuse Large B-cell Lymphoma | December 2015 | |
| NCT02527174 | Withdrawn | Phase 1 | A Study of Volasertib Plus Induction Chemotherapy for Acute Myeloid Leukemia | November 2016 | September 2018 |
| NCT01670084 | Withdrawn | Phase 2 | Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Blastic Phase Chronic Myelogenous Leukemia | December 2012 | September 2017 |
| NCT01478074 | Withdrawn | Phase 1 | ALT-801-activated Natural Killer Cells After FLAG Induction for Acute Myeloid Leukemia | November 2011 | November 2013 |
| NCT00003405 | Withdrawn | Phase 2 | Combination Chemotherapy Plus Biological Therapy in Treating Patients With Acute Myelogenous Leukemia | April 1998 | April 1999 |
| NCT00003407 | Withdrawn | Phase 2 | Amifostine & High-Dose Combination Chemotherapy in Treating Patients With Acute ML or CML | February 13, 2001 | April 7, 2004 |
| NCT02472626 | Withdrawn | Phase 1/Phase 2 | 6,8-Bis(Benzylthio)Octanoic Acid, Cytarabine, and Daunorubicin Hydrochloride in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia | December 2015 | July 2016 |
| NCT04100330 | Withdrawn | Phase 2 | A Study of Ficlatuzumab With HiDAC and HiDAC Alone in Adults With Relapsed or Refractory Acute Myeloid Leukemia | January 31, 2020 | March 27, 2020 |
| NCT03760445 | Withdrawn | Phase 1/Phase 2 | HDM201 Added to CT in R/R or Newly Diagnosed AML | November 15, 2019 | June 13, 2023 |